Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them

ABSTRACT

The present invention relates to novel oxazolidinone compounds of the general formula (I)                  
 
where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutical acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

FIELD OF THE INVENTION

The present invention relates to novel oxazolidinone compounds, theirderivatives, their analogs, their tautomeric forms, their stereoisomers,their polymorphs, their pharmaceutically acceptable salts, theirpharmaceutically acceptable solvates and pharmaceutical compositionscontaining them. More particularly, the present invention relates tonovel oxazolidinones of the general formula (I).

their derivatives, their analogs, their tautomeric forms, theirstereoisomers, their polymorphs, their pharmaceutically acceptablesalts, their pharmaceutically acceptable solvates and pharmaceuticalcompositions containing them.

The present invention also relates to a process for the preparation ofthe above said novel compounds, their derivatives, their analogs, theirtautomeric forms, their stereoisomers, their polymorphs, theirpharmaceutically acceptable salts, their pharmaceutically acceptablesolvates and pharmaceutical compositions containing them.

The present invention also relates to novel intermediates, methods fortheir preparation and their use in the preparation of compounds offormula (I).

Oxazolidinones are useful as antibacterials (J. Med. Chem., 1996, 39,673), antihistamines and anti allergic agents (EP 291,244),anticonvulsants (DE 3,915,184), for treating cognition disorders, asanti psychotics, anti platelet aggregators, antidepressants, sedatives,hypnotics, monoamine oxidase inhibitors (WO 97/13768) and as chiralauxiliaries (Aldrichimica Acta, 1982, 15 23) in asymmetric synthesis.

BACKGROUND OF THE INVENTION

Since the discovery of penicillin, pharmaceutical companies haveproduced more than one hundred antibacterial agents to combat a widevariety of bacterial infections. In the past several years, due to themisuse of these antibiotics there has been rapid emergence of bacterialresistance to several of these antibiotics. The multidrug resistanceamong these bacterial pathogens may also be due to mutation leading tomore virulent clinical isolation, the most disturbing milestone has beenthe acquisition of resistance to vancomycin, an antibiotic generallyregarded as the agent of last resort for serious Gram-positiveinfections. This growing multidrug resistance has recently rekindledinterest in the search for a new structural class of antibiotics thatinhibit or kill these bacteria possibly by novel mechanisms.

A problem of larger dimension is the increasing incidence of the morevirulent, methicillin-resistant Staphylococcus aureas (MRSA) amongclinical isolates found worldwide. As with vancomycin resistantorganisms, many MRSA strains are resistant to most of the knownantibiotics, but MRSA strains have remained sensitive to vancomycin.However, in view of the increasing reports of vancomycin resistantclinical isolates and growing problem of bacterial resistance, there isan urgent need for new molecular entities effective against the emergingand currently problematic Gram-positive organisms.

Recently, several oxazolidinones have been discovered, which inhibitprotein synthesis by binding to the 50S-ribosomal subunit which is closeto the site to which chloramphenicol and lincomycin bind but their modeof action is mechanistically distinct from these two antibiotics.

The new class of oxazolidinones of the present invention is useful forthe treatment of a number of resistant and sensitive gram-positivestrains both in vitro and in vivo. Some of the hitherto known compoundsdescribed in the prior art are outlined below:

(i) International Patent Application WO 93/23384 discloses compounds offormula (IIa)

where

Y represents a hydrogen atom, (C₁–C₆)alkyl or aryl, OH, O(C₁–C₆)alkyl,O-vinyl, O-phenyl, O—C(═O)(C₁–C₆)alkyl, —O—C(═O)-phenyl (phenyl can besubstituted with one to three F, Cl, OCH₃, OH, NH₂, or (C₁–C₄)alkyl) orO—C(═O)—O—CH₃, S—(C₁–C₆)alkyl, SO₂—(C₁–C₆)alkyl, —SO₂—N(R³)₂, (where R³is independently hydrogen, (C₁–C₄)alkyl or phenyl which can besubstituted with one to three F, Cl, OCH₃, OH, NH₂, or (C₁–C₄)alkyl);

—C(═O)—(C₁–C₆)alkyl, —C(═O)—O—(C₁–C₆)alkyl, —C(═O)—N(R³)₂,—C(═O)—CH(R⁴)N(R³)₂, —C(═O)—CH(R⁴)—NH—C(NH)—NH₂ (where R⁴ is an aminoacid side chain); —N(R³)₂, —N(CH₂)_(m) (where m is 2–6 and forms acyclic structure with the nitrogen atom and where one or more carbonatoms can be replaced with S, O or NR³), —C(CH₃)═N—OR or Y representsany of the groups given below:

where

R⁵ is OH, OCH₃, CH₂OH, CH₂OCH₃, CO₂CH₃, CO₂C₂H₅, R⁶ represents CH₃ orhydrogen, R⁷ represents CH₂ or C(═O), R⁸ represents hydrogen or ═O, p is1 or 2, R⁹ represents O, S, S(O), SO₂, CH₂, NH, NCH₃, NC₂H₅, NCHO,NCOCH₃ or NCO₂CH₃, wherein each occurrence of said (C₁–C₆)alkyl may besubstituted with one or more F, Cl, Br, I, OR¹, COOR¹, CN, SR¹ or R¹(where R¹ is a hydrogen or (C₁–C₄)alkyl); X and Z are independently(C₁–C₆) alkyl, (C₃–C₁₂)cycloalkyl or hydrogen or X and Z form a (C₀–C₃)bridging group, preferably X and Z are hydrogen;

U, V and W are independently (C₁–C₆)alkyl, F, Cl, Br, hydrogen or a(C₁–C₆)alkyl substituted with one or more of F, Cl, Br or I, preferablyU and V are F and W is hydrogen;

R is hydrogen, (C₁–C₁₂)alkyl, (C₃–C₁₂)cycloalkyl, (C₁–C₆)alkoxy,(C₁–C₆)alkyl substituted with one or more F, Cl, Br, I or OH, n is 1 or2; and q is 0–4 inclusive.

An example of this class of compounds is shown in formula (IIb)

(ii) International Patent Application WO 98/01447 discloses compounds offormula (IIc)

wherein

R¹ represents —NHC(═O)R^(a) wherein R^(a) represents (C₁–C₄)alkyl;

R² and R³ represent hydrogen or fluoro;

R⁴ and R⁵ are independently hydrogen or methyl;

R⁶ represent pyridyl, optionally substituted by substituents selectedfrom (C₁–C₄)alkyl (optionally substituted), halo, trifluoromethyl,(C₁–C₄)alkyl-S(O)_(n)— (wherein n is 0, 1 or 2), (C₁–C₄)alkyl SO₂amino,(C₁–C₄)alkanoylamino, carboxy, hydroxy, amino, (C₁–C₄)alkylamino,di-(C₁–C₄)alkylamino, (C₁–C₄) alkoxycarbonyl, carbamoyl,N—(C₁–C₄)alkylcarbamoyl, di-(N—(C₁–C₄)alkyl)carbamoyl (wherein the(C₁–C₄)alkyl group on groups in the last two mentioned carbamoyl groupsis optionally substituted by hydroxy, (C₁–C₄)alkoxy or(C₁–C₄)alkoxycarbonyl), (C₂–C₄)alkenyl (optionally substituted bycarboxy or (C₁–C₄)alkoxycarbonyl), (C₁–C₄)alkoxy, cyano, or nitrogroups.

An example of this class of compounds is shown in formula (IId)

(iii) International Patent Application No. WO 95/07271 disclosescompounds of formula (IIe)

wherein

X represents O, S, SO, SO₂, SNR¹⁰ or SONR¹⁰;

R represents hydrogen, (C₁–C₈)alkyl optionally substituted with one ormore of the following: F, Cl, hydroxy, (C₁–C₈)alkoxy, (C₁–C₈)acyloxy or—OCH₂Ph or R represents (C₃–C₆)cycloalkyl, amino, (C₁–C₈)alkylamino,(C₁–C₈)dialkylamino or (C₁–C₈)alkoxy;

R¹ represents hydrogen except when X is O, then R¹ can be hydrogen, CH₃,cyano, —CO₂H, CO₂R or (CH₂)_(m)R¹¹ (m is 1 or 2);

R² represents independently hydrogen, F or Cl; R³ represents hydrogen orCH₃;

R¹⁰ independently represents hydrogen, (C₁–C₄)alkyl (optionallysubstituted with chloro, fluoro, hydroxy, (C₁–C₈)alkoxy, amino,(C₁–C₈)alkylamino, or (C₁–C₈)dialkylamino) or p-toluenesulfonyl;

R¹¹ represents hydrogen, hydroxy, OR, OCOR, NH₂, NHCOR or N(R¹⁰)₂; and nis 0, 1 or 2.

An example of this class of compounds is shown in formula (IIf)

(iv) International Patent Application WO 95/25106 discloses compounds offormula (IIg)

where

R is hydrogen atom, (C₁–C₈)alkyl, (C₃–C₆)cycloalkyl, amino,(C₁–C₈)alkylamino, (C₁–C₈)dialkylamino, (C₁–C₈)alkoxy or (C₁–C₈)halogenalkyl;

R¹ and R³ are each and independently represents hydrogen atom, halogenatom, (C₁C₈)alkyl, (C₃–C₆)cycloalkyl, —(CH₂)_(m)—OR¹¹ or —C(═O)—R⁴¹;

X and Y are each and independently represents hydrogen atom, halogenatom;

R⁴ and R⁵ are each and independently represents hydrogen atom,(C₁–C₈)alkyl, (C₁–C₈)alkoxy, (C₁–C₈)alkylthio, —(CH₂)_(m)—OR⁵¹,—O—(CH₂)_(m)—OR⁵¹, —NR⁴²R⁵², —N═CH—NR⁴²R⁵⁵, —C(═O)—NR⁴²R⁵² or—(CH₂)_(m)—C(═A)—R⁴¹or they may combine together to form ═O, ═NR⁴³, ═S,═CR⁴⁴R⁵⁴ or an optionally substituted, unsaturated or saturated 5 or 6membered hetero ring having 1–3 hetero atoms selected from the groupconsisting of a nitrogen atom, an oxygen atom and a sulfur atom;

R¹¹ and R¹² are each and independently represents hydrogen atom,(C₁–C₈)alkyl or methoxymethyl; R⁴¹ is hydrogen atom, —(CH₂)_(m)—OH,(C₁–C₈)alkyl, (C₁–C₈)alkoxy, —O—CH₂—O—C(═O)—R¹¹ or—(CH₂)_(m)—C(═O)—OR¹¹;

R⁴² and R⁵² are each and independently represents hydrogen atom,—(CH₂)_(m)—OR¹¹, (C₁–C₈)alkyl, —C(═O)—R⁴¹ —C(═O)—NR¹¹R¹²,—(CH₂)_(p)-phenyl, thiazol-2-yl or they may combine together to form apyrrolidino group, a piperidino group, a piperazino group, a morpholinogroup or a thiomorpholino group, each of which may be substituted by(C₁–C₈)alkyl or —(CH₂)_(m)—OH;

R⁴³ is hydrogen atom, —OR⁵¹, (C₁–C₈)alkyl, (C₁–C₈)alkoxy,—(CH₂)_(p)-phenyl, NR⁴²R⁵², —NH—C(═NH)—NH₂, [1,2,4]triazol-4-yl orcyano;

R⁴⁴ and R⁵⁵ are each and independently represents hydrogen atom,(C₁–C₈)alkyl, —C(═O)—R⁴¹ or —(CH₂)_(p)-phenyl;

R⁵¹ is hydrogen atom, (C₁–C₈)alkyl substituted by one or more hydroxy;(C₂–C₈)alkenyl, (C₁–C₈)halogenalkyl, —(CH₂)_(m)—OR¹¹,—(CH₂)_(m)—C(═O)—R⁴¹, —C(═O)—(CH₂)_(m)—OR⁴ or tosyl; A is oxygen atom orethyleneketal;

is a double bond or a simple bond; m's are each and independently 0, 1or 2; n is 0 or 1; p's are each and independently 1, 2, 3 or 4.

An example of this class of compounds is shown in formula (IIh)

(v) International Patent Application WO 96/13502 discloses compounds offormula (IIi)

Q is selected from the structures (a), (b), (c), (d) and (e);

R¹ is H or F, OR⁷, SR⁷, NR⁸R⁹, CN, (C₁–C₄)alkoxycarbonyl, carboxamide,(C₁–C₄)acyl optionally substituted with one or more of the following:fluorine, hydroxy, (C₁–C₄)alkoxy, (C₁–C₄)acyloxy; NHO(C₁–C₆)alkyl orNHOCH₂Ph, NSO₂R where R is (C₁–C₆)alkyl optionally substituted with oneor more F, Cl, (C₁–C₆)alkoxy or phenyl;

R² is independently selected from hydrogen or fluorine, hydroxy, ORwhere R is (C₁–C₆)alkyl; (C₁–C₄)alkyl or Ph;

R³ is independently selected from H, phenyl, pyridyl or (C₁–C₃)alkylwhich can be optionally substituted with F, Cl, hydroxy,(C₁–C₃)alkoxycarbonyl, (C₁–C₃)acyloxy, (C₁–C₃)alkoxy or N(C₁–C₄ alkyl)₂;

R⁴ is independently H, OCH₃, F or Cl; R⁵ is hydrogen, (C₁–C₈)alkyloptionally substituted with one or more of the following: F, Cl,hydroxy, (C₁–C₈)alkoxy, (C₁–C₈)acyloxy; (C₃–C₆)cycloalkyl, amino,(C₁–C₈)alkylamino, (C₁–C₈) dialkylamino, (C₁–C₈)alkoxy;

R⁶ is O, S, NR¹⁰, CR¹¹R¹², (OR)₂, where R is (C₁–C₆)alkyl; O(CH₂)_(m) O,(SR)₂ where R is (C₁–C₆)alkyl; S(CH₂)_(m)S;

R⁷ is H, (C₁–C₈)alkyl optionally substituted with one or more of thefollowing: F, Cl, —CN, OH, (C₁–C₈)alkoxy, (C₁–C₈)acyloxy,(C₁–C₈)alkoxycarbonyl, phenyl; (C₁–C₈)acyl optionally substituted withone or more of the following: hydroxy, (C₁–C₈) alkoxy, (C₁–C₈)acyloxy;(C₁–C₈)alkoxycarbonyl, carboxamide optionally substituted with a(C₁–C₄)alkyl or phenyl on the carboxamide nitrogen; phenyl, optionallysubstituted with one or more of the following: halogen, CN, (C₁–C₃)alkoxy, (C₁–C₃)alkoxycarbonyl, (C₁–C₄)alkyl optionally substituted withone or more of F or (C₁–C₃)alkoxy;

R⁸ and R⁹ are independently selected from H, (C₁–C₈)alkyl optionallysubstituted with one or more of the following: F, Cl, —CN, OH,(C₁–C₈)alkoxy, (C₁–C₈)acyloxy, (C₁–C₈)alkoxycarbonyl, phenyl;(C₁–C₈)acyl optionally substituted with one or more of the following:hydroxy, (C₁–C₈)alkoxy, (C₁–C₈)acyloxy, amino, (C₁–C₄)acylamino, amino(C₁–C₄)acylamino; benzoyl optionally substituted with one or more of thefollowing F, Cl, hydroxy, (C₁–C₈)alkoxy, (C₁–C₈)acyloxy, amino,(C₁–C₄)acylamino, (C₁–C₄)alkoxycarbonylamino; (C₁–C₈)alkoxycarbonyl,benzyloxycarbonyl, tertbutoxycarbonyl; carboxamide optionallysubstituted with a (C₁–C₄)alkyl or phenyl on the carboxamide nitrogen;trifluoracetyl, CO(C₁–C₆ alkyl);

R¹⁰ is H, OR⁷, NHR⁷, (C₁–C₈)alkyl optionally substituted with phenyl;

R¹¹ and R¹² are independently selected from H, F, (C₁–C₄)alkyloptionally substituted with halogen, hydroxy, (C₁–C₄)alkoxy,(C₁–C₄)alkoxycarbonyl, phenyl; (C₁–C₈)acyl, (C₁–C₄)alkoxycarbonyl, CN;

R¹¹ is O or S; R¹⁸ and R¹⁹ are independently selected from H,(C₁–C₄)alkyl optionally substituted with halogen, hydroxy,(C₁–C₄)alkoxy; OH, (C₁–C₄)alkoxy optionally substituted with hydroxy or(C₁–C₄)alkoxy; NR⁸R⁹, —OC(O) (C₁–C₄)alkyl;

R²⁰ is H, CH₃; n is 0 or 1; m is 2 or 3.

An example of this class of compounds is shown in formula (IIj)

(vi) International Patent Application WO 97/27188 discloses compounds offormula (II k)

R¹ is of the formula —NHC(═O)(C₁–C₄)alkyl, —NHS(O)_(n)(C₁–C₄)alkyl,wherein n is 0, 1 or 2 or R¹ is hydroxy;

R² and R³ are independently hydrogen or fluoro;

R⁴ is hydrogen, methyl, ethyl or oxo;

R⁵ is hydrogen, (C₁–C₆)alkyl, (C₂–C₆)alkenyl, (C₂–C₆)alkynyl, or of theformula R⁶(CH₂)_(m) wherein m is 1–4 and R⁶ is trifluoromethyl,difluoromethyl, fluoromethyl, (C₁–C₄)alkoxy, (C₁–C₄)alkyl,S(O)_(p)wherein p is 0, 1 or 2, (C₁–C₆)alkanoyloxy, di-(N—(C₁–C₄)alkyl)amino,N—((C₁–C₄)alkyl)(C₁–C₄)alkanoylamino, cyano, carboxy,(C₁–C₄)alkoxycarbonyl, carbamoyl, -di-(N—(C₁–C₄)alkyl)carbamoyl,N—((C₁–C₄)alkyl)(C₁–C₄)alkanesulphonamido,N¹—((C₁–C₄)alkyl)-di-(N³—(C₁–C₄)alkyl)ureido or of the formula—OC(═O)NR(R⁸) or N(R⁹)SO₂NR⁷(R⁸) wherein R⁷ and R⁸ are independentlyhydrogen or (C₁–C₄)alkyl and R⁹ is (C₁–C₄) alkyl; or

m is 2–4 and R⁶ is hydroxy, (C₁–C₄)alkanoylamino, amino,(C₁–C₄)alkylamino, (C₁–C₄)alkanesulphonamido, ureido,di-(N³—(C₁–C₄)alkyl)ureido or of the formula NHSO₂NR⁷(R⁸).

An example of this compound is shown in fig (III)

(vii) International Patent Application WO 98/01446 discloses compoundsof formula (IIm)

R¹ is of the formula —NHC(═O)R^(a) wherein R^(a) is (C₁–C₄)alkyl;

R² and R³ are independently hydrogen or fluoro;

R⁴ and R⁵ are independently hydrogen or methyl;

R⁶ is a 6-membered heteroaryl ring containing 2 or 3 ring nitrogen atomsas the only ring heteroatoms and optionally substituted by substituentsselected from (C₁–C₄)alkyl (optionally substituted), halo,trifluoromethyl, (C₁–C₄)alkylS(O)_(n-) (wherein n is 0, 1 or 2),(C₁–C₄)alkylS(O)₂ amino, (C₁–C₄)alkanoylamino, carboxy, hydroxy, amino,(C₁–C₄)alkylamino, di(C₁–C₄)alkylamino, (C₁–C₄)alkoxycarbonyl,carbamoyl, N—(C₁–C₄)alkylcarbamoyl, -di-(N—(C₁–C₄)alkyl)carbamoyl,(wherein (C₁–C₄)alkyl group or groups in the last two mentionedcarbamoyl substituents is optionally substituted by hydroxy,(C₁–C₄)alkoxy or (C₁–C₄)alkoxycarbonyl), (C₂–C₄)alkenyl (optionallysubstituted by carboxy or (C₁–C₄)alkoxycarbonyl), (C₁–C₄)alkoxy, cyanoor nitro.

An example of this compound is shown in fig (IIl)

SUMMARY OF THE INVENTION

With an objective to develop novel compounds effective against a numberof human and veterinary pathogens, including gram-positive aerobicbacteria such as MRSA, streptococci and enterococci as well as anaerobicorganisms such as Bacteroides spp, Clostridia spp. species and acid-fastorganisms such as Mycobacterium tuberculosis, Mycobacterium aviumn andMycobacterium spp., we focussed our research to develop new compoundseffective against the above mentioned organisms. Efforts in thisdirection have led to the preparation of compounds having generalformula (I) as defined above.

The present invention provides novel Oxazolidinones of the generalformula (I) as defined above and their derivatives, their analogs, theirtautomeric forms, their stereoisomers, their polymorphs, theirpharmaceutically acceptable salts, their pharmaceutically acceptablesolvates and pharmaceutical compositions containing them, or theirmixtures having enhanced activities, without toxic effect or withreduced toxic effect.

A process for the preparation of novel oxazolidinones of the formula (I)as defined above and their derivatives, their analogs, their tautomericforms, their stereoisomers, their polymorphs, their pharmaceuticallyacceptable salts and their pharmaceutically acceptable solvates is alsodescribed.

An aspect of the present invention is to provide pharmaceuticalcompositions containing compounds of the general formula (I), theiranalogs, their derivatives, their tautomers, their stereoisomers, theirpolymorphs, their salts, solvates or their mixtures in combination withsuitable carriers, solvents, diluents and other media normally employedin preparing such compositions.

Novel intermediates of formulae (VI), (VII), (X), (XVI) and (XVIII) anda process for their preparation and their use in the preparation ofcompounds of formula (I) is also provided.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds having the general formula(I)

where

R¹ represents halo, azido, thioalcohol, isothiocyanate, OR⁴, NHR⁴ orN(R⁴)₂, where R⁴ represents hydrogen atom, or substituted orunsubstituted groups selected from acyl, thioacyl,(C₁–C₆)alkoxycarbonyl, cyclo(C₃–C₆)alkoxythiocarbonyl,(C₂–C₆)alkenyloxycarbonyl, (C₂–C₆)alkenylcarbonyl, aryloxycarbonyl,(C₁–C₆)alkoxythiocarbonyl, (C₂–C₆)alkenyloxythiocarbonyl,aryloxythiocarbonyl, —C(═O)—C(═O)—(C₁–C₆)alkyl, —C(═O)—C(═O)-aryl,—C(═O)—C(═O)—(C₁–C₆)alkoxy, —C(═O)—C(═O)-aryloxy, —(C═S)—S—(C₁–C₆)alkyl,—(C═S)—NH₂, —(C═S)—NH—(C₁–C₆)alkyl, —C(═S)—N—((C₁–C₆)alkyl)₂,—C(═S)—NH—(C₂–C₆)alkenyl, (C═S)—(C═O)—(C₁–C₆)alkoxy,—(C═S)—(C═O)-aryloxy, —C(═S)—O—(C═O)—(C₁–C₆)alkyl,C(═S)—C(═S)—(C₁–C₆)alkyl, —C(═S)—C(═S)-aryl, thiomorpholinylthiocarbonylor pyrrolidinylthiocarbonyl;

R² and R³ may be same or different and independently represent hydrogen,halogen atom, (C₁–C₆)alkyl group, halo(C₁–C₆)alkyl, cyano, nitro,SR^(a), NR^(a), or OR^(a) where R^(a) represents substituted orunsubstituted (C₁–C₆)alkyl group, or halo(C₁–C₆)alkyl;

Z represents S, O, ═CH or NR^(b) where R^(b) represents hydrogen orsubstituted or unsubstituted (C₁–C₆)alkyl, (C₂–C₆)alkenyl,(C₁–C₆)cycloalkyl, (C₁–C₆)alkoxy, aryl, aralkyl, aryloxy,(C₁–C₆)alkylcarbonyl, arylcarbonyl, (C₁–C₆)lkoxycarbonyl oraryloxycarbonyl;

Y¹ represents ═O or ═S group and Y² and Y³ independently representhydrogen, halogen, cyano, nitro, formyl, hydroxy, amino, ═O, ═S group orsubstituted or unsubstituted groups selected from (C₁–C₆)alkyl,hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆)alkyl, (C₁–C₆)alkoxycarbonyl,carboxy(C₁–C₆)alkyl, (C₁–C₆)alkylsulfonyl,(C₁–C₆)alkylcarbonylamino(C₁–C₆)alkyl, arylcarbonylamino C₁–C₆)alkyl,(C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl, amino(C₁–C₆)alkyl,mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino, arylamino, (C₁–C₆)alkoxy,aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl orheterocycloalkyl;

Y² and Y³ when present on adjacent carbon atoms together may also form asubstituted or unsubstituted 5 or 6 membered aromatic or non-aromaticcyclic structure, optionally containing one or two hetero atoms; itsderivatives, its analogs, its tautomeric forms, its stereoisomers, itspolymorphs, its pharmaceutically acceptable salts or itspharmaceutically acceptable solvates.

Suitable groups represented by R⁴ may be selected from hydrogen atom,(C₁–C₇)acyl group such as —C(═O)H, —C(═O)CH₃, —C(═O)CH₂CH₃,—C(═O)(CH₂)₂CH₃, —C(═O)(CH₂)₃CH₃, —C(═O)(CH₂)₄CH₃, —C(═O)(CH₂)₅CH₃,—C(═O)phenyl and the like, the acyl group may be substituted;thio(C₁–C₇)acyl group such as —C(═S)H, —C(═S)CH₃, —C(═S)CH₂CH₃, —C(═S)Phand the like, the thioacyl group may be substituted;(C₁–C₆)alkoxycarbonyl group containing (C₁–C₆)alkyl group which may belinear or branched such as methoxycarbonyl, ethoxycarbonyl,propoxycarbonyl, isopropoxycarbonyl and the like, the(C₁–C₆)alkoxycarbonyl group may be substituted;cyclo(C₃–C₆)alkoxythiocarbonyl group such as cyclopropoxythiocarbonyl,cyclobutoxythiocarbonyl and the like, the cyclo(C₃–C₆)alkoxythiocarbonylmay be substituted; (C₂–C₆)alkenylcarbonyl such as ethenylcarbonyl,propenylcarbonyl, butenylcarbonyl and the like, the(C₂–C₆)alkenylcarbonyl may be substituted; (C₂–C₆)alkenyloxycarbonylgroup such as ethenyloxycarbonyl, propenyloxycarbonyl,butenyloxycarbonyl and the like, the (C₂–C₆)alkenyloxycarbonyl may besubstituted; aryloxycarbonyl group such as phenoxycarbonyl,benzyloxycarbonyl group and the like, the aryloxycarbonyl group may besubstituted; (C₁–C₆)alkoxythiocarbonyl group such as CH₃O—C(═S)—,C₂H₅O—C(═S)—C₃H₇O—C(═S)— and the like, which may be substituted;(C₂–C₆)alkenyloxythiocarbonyl group such as ethenyloxythiocarbonyl,propenyloxythiocarbonyl, butenyloxythiocarbonyl and the like, the(C₂–C₆)alkenyloxythiocarbonyl group may be substituted;aryloxythiocarbonyl group such as phenyl-O—C(═S)—, benzyl-O—C(═S)— andthe like, which may be substituted; —C(═O)—C(═O)—(C₁–C₆)alkyl group suchas —C(═O)—C(═O)methyl, —C(═O)—C(═O)ethyl, —C(═O)—C(═O)propyl and thelike, which may be substituted; —C(═O)—C(═O)-aryl group such as—C(═O)—C(═O)phenyl, —C(═O)—C(═O)naphthyl and the like, which may besubstituted; —C(═O)—C(═O)—(C₁–C₆)alkoxy group such as—C(═O)—C(═O)methoxy, —C(═O)—C(═O)ethoxy, —C(═O)—C(═O)propyloxy and thelike, which may be substituted; —C(═O)—C(═O)-aryloxy group such as—C(═O)—C(═O)phenyloxy, —C(═O)—C(═O)benzyloxy, which may be substituted;—(C═S)—S—(C₁–C₆)alkyl such as —(C═S)—S-methyl, —(C═S)—S-ethyl,—(C═S)—S-propyl and the like, which may be substituted; —(C═S)—NH₂;—(C═S)—NH—(C₁–C₆)alkyl such as —(C═S)—NH-methyl, —(C═S)—NH-ethyl,—(C═S)—NH-propyl and the like, which may be substituted;—C(═S)—N—((C₁–C₆)alkyl)₂ such as —C(═S)—N-(methyl)₂, —C(═S)—N-(ethyl)₂,—C(═S)—N-(propyl)₂ and the like, which may be substituted;—C(═S)—NH—(C₂–C₆)alkenyl such as —C(═S)—NH-ethenyl, —C(═S)—NH-propenyl,—C(═S)—NH-butenyl and the like, which may be substituted;—(C═S)—(C═O)—(C₁–C₆)alkoxy such as —(C═S)—(C═O)-methoxy,—(C═S)—(C═O)-ethoxy, —(C═S)—(C═O)-propoxy and the like, which may besubstituted; —(C═S)—(C═O)-aryloxy such as —(C═S)—(C═O)-phenyloxy,—(C═S)—(C═O)-naphthyloxy and the like, which may be substituted;—C(═S)—O—(C═O)—(C₁–C₆)alkyl such as —C(═S)—O—(C═O)-methyl,—C(═S)—O—(C═O)-ethyl, —C(═S)—O—(C═O)-propyl and the like, which may besubstituted; —C(═S)—C(═S)—(C₁–C₆)alkyl group such as —C(═S)—C(═S)methyl,—C(═S)—C(═S)ethyl, —C(═S)—C(═S)propyl and the like, which may besubstituted; —C(═S)—C(═S)aryl group such as —C(═S)—C(═S)phenyl,—C(═S)—C(═S)naphthyl and the like, which may be substituted;thiomorpholinylthiocarbonyl or pyrrolidinylthiocarbonyl.

When the groups represented by R⁴ are substituted, the substituents maybe selected from halogen atom such as chlorine, fluorine, bromine andiodine; hydroxy, amino, mono(C₁–C₆)alkylamino such as methylamino,ethylamino, propylamino and the like, di(C₁–C₆)alkylamino such asdimethylamino, diethylamino, methylethylamino, dipropylamino,ethylpropylamino and the like, cyano, nitro, alkoxy, aryl, hydroxyaryl,pyridyl, hydroxyalkyl, alkoxyaryl or carboxyl and its derivatives.Alkoxy is a (C₁–C₆)alkoxy group and aryl is phenyl or naphthyl.

Suitable groups represented by R² and R³ may be selected from hydrogen,halogen atom such as fluorine, chlorine or bromine; (C₁–C₆)alkyl groupsuch as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl,n-pentyl, iso-pentyl, n-hexyl and the like; halo(C₁–C₆)alkyl group suchas halomethyl, haloethyl, halopropyl, trihalomethyl and the like,wherein the halo group is selected from fluorine, chlorine, bromine oriodine; cyano, nitro; SR^(a), NR^(a), OR^(a) where R^(a) representssubstituted or unsubstituted (C₁–C₆)alkyl group such as methyl, ethyl,propyl, isopropyl and the like; halo(C₁–C₆)alkyl such as halomethyl,haloethyl, halopropyl, haloisopropyl and the like, where the halo groupis selected from fluro, chloro, bromo or iodo.

The substituents on R^(a) are selected from hydroxy, halogen, nitro,amino, alkoxy, carboxyl or cyano. Alkoxy is a (C₁–C₆)alkoxy group.

Suitable groups represented by Z may be selected from S, O, ═CH orNR^(b) where R^(b) represents hydrogen or substituted or unsubstituted(C₁–C₆)alkyl such as methyl, ethyl, propyl and the like, which may besubstituted; (C₂–C₆)alkenyl such as ethenyl, propenyl, butenyl and thelike, which may be substituted; (C₁–C₆)cycloalkyl such as cyclopropyl,cyclobutyl and the like, which may be substituted; (C₁–C₆)alkoxy such asmethoxy, propoxy, isopropoxy and the like, which may be substituted;aryl group such as phenyl, naphthyl and the like, which may besubstituted; aralkyl such as benzyl, phenethyl and the like, which maybe substituted; aryloxy such as phenyloxy, naphthyloxy and the like,which may be substituted; (C₁–C₆)alkylcarbonyl such as methylcarbonyl,ethylcarbonyl, propylcarbonyl and the like, which may be substituted;arylcarbonyl such as phenylcarbonyl, naphthylcarbonyl and the like,which may be substituted; (C₁–C₆)alkoxycarbonyl such as methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl and the like, which may be substituted;or aryloxycarbonyl such as phenyloxycarbonyl, naphthyloxycarbonyl andthe like, which may be substituted.

The substituents on R^(b) are selected from hydroxy, halogen,pyrrolidinylthiocarbonyl, nitro, amino, alkoxy, carboxyl or cyano.Alkoxy is a (C₁–C₆)alkoxy group.

Y¹ represents ═O or ═S group, Y² and Y³ are selected from hydrogen,halogen such as fluorine, chlorine, bromine or iodine; cyano, nitro,formyl, hydroxy, amino, ═O, ═S group, substituted or unsubstituted(C₁–C₆)alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl,iso-butyl, t-butyl and the like; hydroxy(C₁–C₆)alkyl such ashydroxymethyl, hydroxyethyl, hydroxypropyl and the like, which may besubstituted; (C₁–C₆)alkoxy(C₁–C₆)alkyl group such as methoxymethyl,methoxyethyl, ethoxyethyl, ethoxymethyl, methoxypropyl, propoxymethyl,propoxyethyl and the like, which may be substituted;(C₁–C₆)alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl andthe like, which may be substituted; carboxy(C₁–C₆)alkyl such asCH₃—COOH, CH₃—CH₂—COOH and the like, which may be substituted;(C₁–C₆)alkylsulfonyl group such as methylsulfonyl, ethylsulfonyl and thelike, which may be substituted; (C₁–C₆)alkylcarbonylamino(C₁–C₆)alkylgroups such as methylcarbonylaminomethyl, ethylcarbonylaminomethyl,methylcarbonylaminoethyl, ethylcarbonylaminoethyl and the like, whichmay be substituted; arylcarbonylamino(C₁–C₆)alkyl such asphenylcarbonylaminomethyl, phenylcarbonylaminoethyl,naphthylcarbonylaminomethyl, naphthylcarbonylaminoethyl and the like,which may be substituted; (C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl group suchas methylcarbonyloxymethyl, ethylcarbonylxoymethyl,methylcarbonyloxyethyl, propylcarbonyloxymethyl, propylcarbonyloxyethyl,propylcarbonyloxypropyl and the like, which may be substituted;amino(C₁–C₆)alkyl such as aminomethyl, aminoethyl, aminopropyl and thelike, which may be substituted; mono(C₁–C₆)alkylamino such asmethylamino, ethylamino, propylamino and the like, which may besubstituted; di(C₁–C₆)alkylamino such as dimethylamino, diethylamino,methylethylamino, dipropylamino, ethylpropylamino and the like, whichmay be substituted; arylamino such as phenylamino, benzylamino and thelike, which may be substituted; (C₁–C₆)alkoxy group such as methoxy,ethoxy, propoxy, isopropoxy and the like, which may be substituted; arylgroup such as phenyl, naphthyl and the like, which may be substituted;aryloxy group such as phenoxy, naphthyloxy and the like, the aryloxygroup may be substituted; aralkyl such as benzyl, phenethyl,C₆H₅CH₂CH₂CH₂, naphthylmethyl and the like, the aralkyl group may besubstituted; heteroaryl groups such as pyridyl, thienyl, furyl,pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,tetrazolyl, benzopyranyl, benzofuranyl and the like, which may besubstituted; heteroaralkyl such as imidazolemethyl, imidazoleethyl,pyridylmethyl, furyl methyl, oxazolemethyl, imidazolyl and the like,which may be substituted; heterocyclyl group such as pyrrolidinyl,piperidinyl, morpholinyl, piperazinyl and the like; heterocycloalkylgroups such as pyrrolidinemethyl, piperidinemethyl, morpholinemethyl,piperazinemethyl and the like, which may be substituted.

When the groups represented by Y² and Y³ are substituted, thesubstituents may be selected from hydroxy, nitro, cyano, amino,(tert-butyldimethylsilyloxy) TBSO, halogen atom, (C₁–C₆)alkyl,(C₁–C₆)alkoxy, (C₃–C₆)cycloalkyl, aryl group such as phenyl, naphthyland the like, benzyloxy, acyl group such as formyl, acetyl, and thelike, carboxyl or acyloxy group such as formyloxy, acetyloxy and thelike.

Suitable cyclic structure formed by Y² and Y³ when present on adjacentcarbon atoms which they are attached may be selected from substituted orunsubstituted benzene, pyridine, pyrrolidine, furan, thiophene,morpholine, piperazine, pyrrole and the like.

Pharmaceutically acceptable salts forming part of this invention includesalts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu,Zn, and Mn; salts of organic bases such as N,N′-diacetylethylenediamine,betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol,N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine,hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine,piperidine, procaine, purines, theobromine, triethylamine,trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine,ethylenediamine, N,N′-diphenylethylenediamine,N,N′-dibenzylethylenediamine, N-benzyl phenylethylamine, choline,choline hydroxide, dicyclohexylamine, metformin, benzylamine,phenylethylamine, dialkylamine, trialkylamine, thiamine,aminopyrimidine, aminopyridine, purine, spermidine, and the like; chiralbases like alkylphenylamine, glycinol, phenyl glycinol and the like,salts of natural amino acids such as glycine, alanine, valine, leucine,isoleucine, norleucine, tyrosine, cystine, cysteine, methionine,proline, hydroxy proline, histidine, ornithine, lysine, arginine,serine, threonine, phenylalanine; unnatural amino acids such asD-isomers or substituted amino acids; guanidine, substituted guanidinewherein the substituents are selected from nitro, amino, alkyl such asmethyl, ethyl, propyl and the like; alkenyl such as ethenyl, propenyl,butenyl and the like; alkynyl such as ethynyl, propynyl and the like;ammonium or substituted ammonium salts and aluminum salts. Salts mayinclude acid addition salts where appropriate which are, sulphates,nitrates, phosphates, perchlorates, borates, halides, acetates,tartrates, maleates, citrates, succinates, palmoates,methanesulphonates, benzoates, salicylates, hydroxynaphthoates,benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and thelike. Pharmaceutically acceptable solvates may be hydrates or comprisingother solvents of crystallization such as alcohols.

Particularly useful compounds according to this invention include:

-   (5R)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one    or its salts;    -   (5R)-3-[3-fluoro-4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-[3-fluoro-4-(2-thioxo-1,3-thiazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   3-{2-fluoro-4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-one        or its salts;    -   3-{2-fluoro-4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-6-methyl-2,3-dihydrobenzo[d][1,3]oxazol-2-one        or its salts;    -   3-{2-fluoro-4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-5-methyl-2,3-dihydrobenzo[d][1,3]oxazol-2-one        or its salts;    -   (5R)-5-hydroxymethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-[2-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-[3,5-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-hydroxymethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   3-{4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-one        or its salts;    -   (5R)-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-{3-fluoro-4-[3-(4-methoxybenzyl)-4-oxo-1-imidazolidinyl]phenyl}-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-[3-fluoro-4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-hydroxymethyl-3-[4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-hydroxymethyl-3-[4-(3-benzyl-2-oxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-3-{3-fluoro-4-[3-(fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl}-5-hydroxymethyl-1,3-oxazolan-2-one        or its salts;    -   (5R)-azidomethyl-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-azidomethyl-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   3-{4-[(5R)-5-azidomethyl-2-oxo-1,3-oxazolan-3-yl]-2-fluorophenyl}-6-methyl-2,3-dihydro        benzo[d][1,3]oxazol-2-one or its salts;    -   3-{4-[(5R)-5-azidomethyl-2-oxo-1,3-oxazolan-3-yl]-2-fluorophenyl}-5-methyl-2,3-dihydro        benzo[d][1,3]oxazol-2-one or its salts;    -   (5R)-5-azidomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-azidomethyl-3-[2-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-azidomethyl-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-azidomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   3-{4-[(5R)-5-azidomethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-one        or its salts;    -   (5R)-5-azidomethyl-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-azidomethyl-3-[3-fluoro-4-(3-phenyl-2-oxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-azidomethyl-3-{3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl}-1,3-oxazolan-2-one        or its salts;    -   (5R)-aminomethyl-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-aminomethyl-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-aminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-aminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-aminomethyl-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5R)-5-aminomethyl-3-[3-fluoro-4-(3-benzyl-4-oxo-1-imidazolidinyl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   N-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methanamide        or its salts;    -   N-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methanamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}propanamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}butanamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}pentanamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}heptanamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acrylamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-2,2,2-trifluoroacetamide        or its salts;    -   Ethyl(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl        carbamoylmethanoate or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-2-oxo-3-[3-fluoro-4-(2-thioxo-1,3-thiazolan-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)henyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(6-methyl-2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(5-methyl-2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}propanamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}heptanamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}acrylamide        or its salts;    -   N1-{(5S)-3-[2-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}propanamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-benzyl-4-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[4-(3-benzyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-phenyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamide        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)acetamide        or its salts;    -   (5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(3,3,3-trifluoro-1-thioxopropylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   3-{2-fluoro-4-[(5S)-2-oxo-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-one        or its salts;    -   (5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxopropylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3-fluoro-4-(3-phenyl-2-oxo-1-imidazolidinyl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-one        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylcarbamate        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}methylcarbamate        or its salts;    -   N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]oxo-1,3-oxazolan-5-ylmethyl}methylcarbamate        or its salts;    -   N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylcarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylcarbamate        or its salts;    -   (5S)-5-methylthioxy(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methyldithiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}trifluoroacetoxythiocarbamate        or its salts;    -   (5S)-5-cyclohexyloxy(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-1-propylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-thioxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-2-propylthiocarbamate        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-1-propylthiocarbamate        or its salts;    -   (5S)-5-[2,2,2-trifluoroethyloxy(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-[2-hydroxyethyloxy        (thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-[2-methoxyethyloxy(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}allylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-2-propylthiocarbamate        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-2-oxo-3-[4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(3-methyl-4-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(3-benzyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[4-(3-benzyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-phenyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-phenyl-2-oxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)methylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)ethylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-2-propylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-methoxymethyl-4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)methylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-benzyl-4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)methylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-benzyl-4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)ethylthiocarbamate        or its salts;    -   N1-((5S)-3-{4-[2-oxo-1,3-oxazolan-3yl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-(N,N-dimethylamino)ethylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-(4-methoxybenzyl)-4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)methylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-benzyl-4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)isopropylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[3-hydroxymethyl-4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)methylthiocarbamate        or its salts;    -   N1-((5S)-3-{3-fluoro-4-[4-oxo-1-imidazolidinyl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)methylthiocarbamate        or its salts;    -   N1-{(5S)-3-[3-fluoro-4-(3-methyl-4-thioxo-1-imidazolidinyl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamate        or its salts;    -   (5S)-5-[(2S)-2-hydroxymethylazolan-1-yl(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-diethylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-allylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-benzylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-[4-methoxybenzylamino(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-[2-pyridylmethylamino(thioxo)methylaminomethyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-methylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-[2-hydroxyethylamino(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-[1,4-thiazinan-4-yl(thioxo)methylaminomethyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-[2-pyridylamino(thioxo)methylaminomethyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-5-amino(thioxo)methylaminomethyl-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-methylamino(thioxo)methylamino        methyl-1,3-oxazolan-2-one or its salts;    -   (5S)-5-amino(thioxo)methylaminomethyl-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-one        or its salts;    -   (5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-methylamino(thioxo)methylaminomethyl-1,3-oxazolan-2-one        or its salts and    -   N1-((5S)-3-{4-[2-oxo-1,3-oxazolan-3yl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-(N,N-dimethylamino)ethylthiocarbamate        hydrochloride.

The present invention also relates to a process for the preparation ofthe compound of formula (I) where R¹ represents NHR⁴, wherein R⁴represents hydrogen atom and all other symbols are as defined earlier,which comprises:

(i) reacting a compound of formula (III)

where all the symbols are as defined earlier, with a compound of formula(IV)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; R² and R³ are as defined earlier, toproduce a compound of formula (V)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(ii) reducing the compound of formula (V) to produce a compound offormula (VI)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(iii) reacting the compound of formula (VI) with alkylchloroformate, toproduce a compound of formula (VII)

where R^(c) represents (C₁–C₈)alkyl group such as methyl, ethyl, propyl,benzyl, allyl group and the like; Y¹, Y², Y³, R², R³ and Z are asdefined earlier,

(iv) reacting the compound of formula (VII) with a compound of formula(VIII)

where R¹² represents a (C₁–C₃)alkyl group such as methyl, ethyl orpropyl in the presence of a base to produce a compound of formula (I)

where R¹ represents hydroxy; Y¹, Y², Y³, R², R³ and Z are as definedearlier,

(v) reacting the compound of formula (I) with alkylsulfonyl chloride oraryl sulfonyl chloride to produce a compound of formula (I), where R¹represents alkyl sulfonyl or aryl sulfonyl, which in turn was reactedwith NaN₃ to produce compound of formula (I)

where R¹ represents azido; Y¹, Y², Y³, R², R³ and Z are as definedearlier and

(vi) reducing the compound of formula (I) wherein R¹ represents azidogroup, to produce compound of formula (I)

where R¹ represents NHR⁴ wherein R⁴ represents hydrogen atom; Y¹, Y²,Y³, R², R³ and Z are as defined earlier.

The reaction of a compound of formula (III) with a compound of formula(IV) to produce a compound of formula (V) may be carried out using abase such as KOH, NaOH, K₂CO₃, Na₂CO₃, NaH, KH, triethylamine,diisopropylethyl amine and the like. The reaction may be carried outusing a solvent such as DMSO, DMF, THF, acetonitrile, chloroform and thelike or mixtures thereof. The reaction may be carried out in inertatmosphere, which may be maintained using inert gases such as N₂ or Ar.The reaction may be carried out at a temperature in the range of 20°C.–100° C., preferably at a temperature in the range of ambient −80° C.The reaction time may range from 1 to 15 h, preferably from 6 to 12 h.

The reduction of a compound of formula (V) to produce a compound offormula (VI) may be carried out in the presence of gaseous hydrogen anda catalyst such as Ru, Pd, Rh, Pt, Ni on solid beads such as charcoal,alumina, asbestos and the like. The reduction may be conducted in thepresence of a solvent such as dioxane, acetic acid, ethyl acetate, THF,alcohol such as methanol, ethanol and the like or mixtures thereof. Apressure between atmospheric pressure to 60 psi may be used. Thereaction may be carried out at a temperature in the range of 25 to 60°C., preferably at room temperature. The reaction time ranges from 2 to48 h. The reduction may also be carried out by employing metal inmineral acids such Sn/HCl, Fe/HCl, Zn/HCl, Zn/CH₃CO₂H and the like.

The conversion of compound of formula (VI) to compound of formula (VII)may be carried out with alkylchloroformates such as methychloroformate,ethylchloroformate, propylchloroformate, benzylchloroformate and thelike. The solvent of the reaction may be selected from water, acetone,tetrahydrofuran (THF), acetonitrile, dichloromethane (DCM) and the likeor mixtures thereof. The reaction may be carried out in the presence ofbase such as K₂CO₃, Na₂CO₃, NaH, KOH, triethylamine and the like. Thetemperature of the reaction may be carried out in the presence of 0 to60° C., preferably at 0° C. to room temperature. The time of thereaction is maintained in the range of 1–12 h, preferably in the rangeof 1–4 h.

The reaction of a compound of formula (VII) with a compound of formula(VIII) to produce a compound of formula (I), where R¹ represents hydroxygroup, defined above may be carried out in the presence of a base suchas alkali metal hydrides like NaH or KH or organolithiums like CH₃Li,BuLi, LDA and the like or alkoxides such as NaOMe, NaOEt, t-BuOK. Thereaction may be carried out in the presence of a solvent such as THF,dioxane, DMF, DMSO, DME and the like or mixtures thereof.Hexamethylphosphamide (HMPA) may be used as a cosolvent. The reactiontemperature may range from −78 to 150° C., preferably at a temperaturein the range of −78 to 30° C. The duration of the reaction may rangefrom 3 to 12 h.

The compound of formula (I) where R¹ represents OH is converted tocompound of formula (I) where R¹ represents alkylsulfonyl orarylsulfonyl by treating with alkylsulfonylchloride orarylsulfonylchloride such as methanesulfonyl chloride, p-toluenesulfonylchloride and the like. The reaction may be carried out in the presenceof chloroform, dichloromethane, THF, dioxane and the like or mixturesthereof. The base used in the reaction may be selected from Et₃N,diisopropyl ethylamine, Na₂CO₃, K₂CO₃ and the like. The temperature ofthe reaction is maintained in the range of 0 to 50° C., preferably inthe range of 0 to room temperature. The time of the reaction should bemaintained in the range of 1–12 h, preferably in the range of 1–4 h. Thecompound of formula (I) where R¹ represents alkylsulfonyl orarylsulfonyl is converted to compound of formula (I) where R¹ representsazido group, by treating with NaN₃. The solvent used in the reaction maybe selected from dimethylformamide (DMF), dimethyl sulfoxide (DMSO),methylcyanide and the like. The temperature of the reaction ismaintained in the range of room temperature to 120° C., preferably roomtemperature to 80° C. The time of the reaction is maintained in therange of 1–12 h, preferably 1–4 h.

The reduction of a compound of formula (I) where R¹ represents azidogroup, to produce a compound of formula (I) where R¹ represents NHR⁴wherein R⁴ represents hydrogen atom, may be carried out in the presenceof gaseous hydrogen and a catalyst such as Ru, Pd, Rh, Pt, Ni on solidbeads such as charcoal, alumina, asbestos and the like. The reductionmay be conducted in the presence of a solvent such as dioxane, aceticacid, ethyl acetate, THF, alcohol such as methanol, ethanol and the likeor mixtures thereof. A pressure between atmospheric pressure to 60 psimay be used. The reaction may be carried out at a temperature in therange of 25 to 60° C., preferably at room temperature. The reaction timeranges from 2 to 48 h. The reduction may also be carried out byemploying PPh₃ in water.

In still another embodiment of the present invention there is providedanother process for the preparation of compound of formula (I) where R¹represents hydroxy and all the symbols are as defined earlier, whichcomprises:

(i) reacting the compound of formula (VI)

where all the symbols are as defined earlier, with a compound of formula(IX)

where R¹ represents hydroxy, to produce a compound of formula (X)

where R¹ represents hydroxy; Y¹, Y², Y³, R², R³ and Z are as definedearlier, and

(ii) carbonylating the compound of formula (X) with a suitablecarbonylating agent to produce the compound of formula (I) where R¹represents hydroxy and all other symbols are as defined above.

The reaction of a compound of formula (VI) defined above with a compoundof formula (IX) defined above to produce a compound of formula (X) maybe carried out in the presence or absence of a base such as K₂CO₃, NaH,t-BuOK and the like or mixtures thereof. The reaction may be carried outin the presence of a solvent such as DMF, toluene, THF, CH₃CN, and thelike or mixtures thereof. The reaction may also be carried out in thepresence of Lewis acids such as BF₃.OEt₂, ZnCl₂, Ti(OiPr)₄, lanthanidemetal complexes and the like in the presence of DCE, DMF, THF and thelike or mixtures thereof. The reaction temperature may be in the rangeof 0 to 120° C., preferably at a temperature in the range of 0 to 100°C. The reaction time may range from 3 to 24 h, preferably from 4 to 12h.

The conversion of compound of formula (X) to a compound of formula (I)may be carried out using a carbonylating agent such as dialkylcarbonate, dihalo carbonyl, 1,1′-carbonyldiimidazole and the like in thepresence or absence of a base. The base may be selected fromtriethylamine, tributylamine, diisopropylethylamine,1,4-diazabicyclo(2.2.2)octane (DABCO),1,8-diazabicyclo(5.4.0)undec-7-ene (DBU),1,1,5-diazabicyclo(4.3.0)non-5-ene (DBN), alkoxides like NaOMe, NaOEtand the like or the inorganic bases such as NaOH, KOH and the like. Thereaction may be carried out in the presence of solvents such asdichloromethane, THF, DMF, ethyl acetate and the like or mixturesthereof. The reaction temperature may be in the range of −20 to 135° C.,preferably at a temperature in the range of 15 to 80° C. The reactiontime may range from 2 to 72 h, preferably from 2 to 50 h.

In still another embodiment of the present invention there is providedyet another process for the preparation of compound of the formula (I)where R¹ represents azido and all other symbols are as defined earlier,which comprises:

(i) reacting a compound of formula (VII)

where R^(c) represents (C₁–C₈)alkyl group such as methyl, ethyl, propyl,benzyl, allyl group and the like; and all other symbols are as definedearlier, with a compound of formula (XI)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; to produce a compound of formula (XII)

where R^(c), Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(ii) converting the compound of formula (XII) defined above to acompound of formula (XIII)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier, and

(iii) converting the compound of formula (XIII) defined above to acompound of formula (I) by reacting with organic or inorganic azide,

where R¹ represents azido group; Y¹, Y², Y³, R², R³ and Z are as definedearlier.

The reaction of a compound of formula (VII) with a compound of formula(XI) may be carried out in the presence of base such as NaH, KH, K₂CO₃,t-BuOK, LDA, NaOMe, with or without phase transfer catalyst such astetrabutylammonium halide and the like. The reaction may be carried outin the presence of a suitable solvent such as THF, DMF, DMSO, benzeneand the like or mixtures thereof. The reaction may be carried out at atemperature in the range of −78 to 120° C., preferably at −78 to 60° C.The reaction time may range from 2 to 20 h, preferably from 4 to 10 h.

The conversion of a compound of formula (XII) to a compound of formula(XIII) defined above may be carried in the presence of reagents such asI₂, KI, or NaI. The reaction may be carried out in the presence ofsolvent such as CHCl₃, CH₂Cl₂, THF, DMF, DMSO, acetonitrile and the likeor mixtures thereof. The reaction temperature may be in the range of 0to 100° C., preferably at ambient temperature. The reaction time mayrange from 2 to 24 h, preferably from2to 12 h.

The conversion of a compound of formula (XIII) to a compound of formula(I) where R¹ represents azido group, may be carried out in the presenceof one or more equivalents of metal azide such as LiN₃, NaN₃ or trialkylsilylazide. The reaction may be carried out in the presence of solventsuch as THF, acetone, DMF, DMSO and the like or mixtures thereof. Thereaction may be carried out in inert atmosphere, which may be maintainedusing N₂ or Ar. The reaction may be carried out at a temperature in therange of ambient temperature to reflux temperature of the solvent,preferably at a temperature in the range of 50 to 80° C. The reactiontime may range from 0.5 to 18 h, preferably 1 to 4 h.

In yet another embodiment of the present invention, there is provided aprocess for the preparation of compound of formula (I), where R¹represents hydroxy group and all other symbols are as defined earlier,which comprises:

(i) reacting a compound of formula (VII)

where all the symbols are as defined earlier, with a compound of formula(XIV)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; to produce a compound of formula (XV)

where R^(c), Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(ii) hydrolysing the acetonide moiety in the compound of formula (XV)using conventional methods to produce a compound of formula (XVI)

where R^(c), Y¹, Y², Y³, R², R³ and Z are as defined earlier, and

(iii) cyclising the compound of formula (XVI) with or without a base toa compound of formula (I)

where R¹ represents hydroxy group and all other symbols are as definedearlier.

The reaction of a compound of formula (VII) with a compound of formula(XIV) to produce a compound of formula (XV) may be carried out in thepresence of a base. The base employed may be selected from K₂CO₃, NaH,t-BuOK, LDA and the like. The reaction may be carried out in thepresence of a solvent such as DMF, THF, DMSO, EtOH and the like. Thereaction may be carried at a temperature in the range of −78 to 120° C.,preferably at a temperature in the range of −78 to 1 00° C. The reactiontime may range from 2 to 24 h, preferably from 2 to 20 h.

The hydrolysis of a compound of formula (XV) to produce a compound offormula (XVI) may be carried out using dilute mineral acid such as HCl,H₂SO₄ and the like, organic acids such as aqueous acetic acid, p-toluenesulfonic acid, camphorsulfonic acid, trifluoro acetic acid and the like.The reaction may be carried out in the presence of suitable solvent suchas water, methanol, THF, dioxane and the like or mixtures thereof. Thereaction may be carried at a temperature in the range of 30 to 100° C.,preferably at a temperature in the range of 30 to 60° C. The reactiontime may range from 10 min to 5 h, preferably from 30 min to 2.5 h.

The conversion of a compound of formula (XVI) to a compound of formula(I) where R represents hydroxy group, may be carried out by using a basesuch as NaOMe, K₂CO₃, NaH and the like, in presence of a solvent such asMeOH, DMF, THF, and the like. The duration and temperature of thereaction are maintained in the range of 2 to 4 h and room temperature to150° C. respectively.

In still another embodiment of the present invention there is provided aprocess for the preparation of compounds of formula (I) where R¹represents azido group and all other symbols are as defined earlier,which comprises:

(i) reacting a compound of formula (VII)

where all the symbols are as defined earlier, with a compound of formula(XVII)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; to produce a compound of formula (XVIII)

where R^(c), Y¹, Y², Y³, R², R³ and Z are as defined earlier, and

(ii) converting the compound of formula (XVIII) defined above to acompound of formula (I) by reacting with an organic or an inorganicazide,

where R¹ represents azido group; Y¹, Y², Y³, R², R³ and Z are as definedearlier,

The reaction of a compound of formula (VII) defined above with acompound of formula (XVII) defined above may be carried out in thepresence of a base such as NaH, NaOMe, K₂CO₃, n-BuLi, LDA and the like.The reaction may be carried out in the presence of a solvent such asDMF, THF, DMSO, benzene and the like or mixtures thereof. The reactionmay be carried out at a temperature in the range of −78 to 70° C.preferably at a temperature in the range of −78 to 50° C. The reactiontime may range from 1 to 15 h preferably 1 to 10 h.

The conversion of a compound of formula (XVIII) to a compound of formula(I) where R¹ represents azido group, may be carried out in the presenceof one or more equivalent of metal azide such as LiN₃, NaN₃ or trialkylsilylazide. The reaction may be carried out in the presence of solventsuch as THF, acetone, DMF, DMSO and the like or mixtures thereof. Thereaction may be carried out in inert atmosphere, which may be maintainedby using N₂ or Ar. The reaction may be carried out at a temperature inthe range of ambient temperature to reflux temperature of the solvent,preferably at a temperature in the range of 50 to 80° C. The reactiontime may range from 0.5 to 18 h, preferably 1 to 4 h.

In still another embodiment of the present invention there is providedyet another process for the preparation of compound of the formula (I),where R¹ represents NHR⁴, wherein R⁴ represents acetyl group and allother symbols are as defined earlier, which comprises:

(i) reacting a compound of formula (VII)

where all the symbols are as defined earlier, with a compound of formula(XIX)

to produce a compound of formula (I)

where R¹ represents NHR⁴, where R⁴ represents acetyl group; and Y¹, Y²,Y³, R², R³ and Z are as defined earlier.

The compound of formula (VII) defined above may be converted to acompound of formula (I) defined above, by reacting with compound offormula (XIX) in presence of a base such as NaH, LDA, BuLi and the like.The reaction may be carried out at a temperature in the range of −78 to100° C., preferably in the range of −78 to 80° C. The reaction time mayrange from 3 to 10 h.

In yet another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where R¹represents NHR⁴, wherein R⁴ represents formyl group; from compound offormula (I) where R¹ represents NHR⁴ wherein R⁴ represents hydrogenatom,

where all other symbols are as defined earlier.

The reaction of compound of formula (I) where R¹ represents NHR⁴ whereinR⁴ represents hydrogen atom, to produce a compound of formula (I), whereR¹ represents NHR⁴, wherein R⁴ represents formyl group, may be carriedout in presence of alkyl formates such as methyl formate, ethyl formateand the like. The duration of the reaction may range from 4 to 48 h,prefereably 12 to 24 h. The reaction may be carried out at a temperaturein the range of 60 to 120° C., preferably at reflux temperature.

In another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where R¹represents NHR⁴, wherein R⁴ represents —C(═O)—R^(4a), where R^(4a)represents (C₁–C₆)alkyl, (C₁–C₆)alkoxy, (C₂–C₆)alkenyl,halo(C₁–C₆)alkyl, aryloxy, (C₂–C₆)alkenyloxy, aryloxycarbonyl or(C₁–C₆)alkoxycarbonyl; from a compound of formula (I) where R¹represents NHR⁴ wherein R⁴ represents hydrogen atom,

where all other symbols are as defined earlier.

The compound of formula (I), where R¹ represents NHR⁴, wherein R⁴represents —C(═O)—R^(4a), R^(4a) represents (C₁–C₆)alkyl, (C₁–C₆)alkoxy,(C₂–C₆)alkenyl, halo(C₁–C₆)alkyl, aryloxy, (C₂–C₆)alkenyloxy,aryloxycarbonyl or (C₁–C₆)alkoxycarbonyl, may be prepared from compoundof formula (I) where R¹ represents NHR⁴ wherein R⁴ represents hydrogenatom, by treating with appropriate halide such as acyl chloride likeacetyl chloride, propionyl chloride and the like; alkylchloroformatelike methylchloroformate, ethylchloroformate and the like;aralkylchloroformate like benzylchloroformate and the like. The reactionmay be carried out in the presence of a solvent such as CH₂Cl₂, CHCl₃,toluene, THF and the like or mixtures thereof. The reaction may becarried out in the presence of a base like Et₃N, diisopropyl ethylamine,K₂CO₃, NaH, KOt-Bu and the like. The reaction may be carried at atemperature in the range of −20 to 60° C., preferably at a temperaturein the range of 0 to room temperature. The reaction time may range from1 to 12 h, preferably from 1 to 4 h.

Alternatively, the compound of formula (I), where R¹ represents NHR⁴wherein R⁴ represents acetyl group, may be prepared by reacting compoundof formula (I) where R¹ represents azido group, by treating withthioacetic acid.

The compound of formula (I) where R¹ represents azido group may beconverted to a compound of formula (I) where R¹ represents NHR⁴ whereinR⁴ represents acetyl group by using thioacetic acid, with or withoutusing a solvent such as THF, DMF, toluene and the like. The reaction maybe carried out at a temperature in the range of 25 to 40° C., preferablyat room temperature. The reaction may range from 3 to 24 h, preferablyfrom 4 to 12 h.

In another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where R¹represents NHR⁴, wherein R⁴ represents —C(═S)—R^(4b), wherein R^(4b)represents (C₁–C₆)alkyl, halo(C₁–C₆)alkyl, —C(═O)—(C₁–C₆)alkoxy,—C(═O)-aryloxy, —C(═S)—(C₁–C₆)alkyl or —C(═S)-aryl; from compound offormula (I), where R¹ represents NHR⁴, wherein R⁴ represents—C(═O)—R^(4b), wherein R^(4b) represents (C₁–C₆)alkyl, halo(C₁–C₆)alkyl,C(═O)—(C₁–C₆)alkoxy, —C(═O)-aryloxy, —C(═S)—(C₁–C₆)alkyl or —C(═S)-aryl.

where all symbols are as defined earlier.

Conversion of compound of formula (I), where R¹ represents NHR⁴, whereinR⁴ represents —C(═O)—R^(4b), wherein R^(4b) represents (C₁–C₆)alkyl,halo(C₁–C₆)alkyl, —C(═O)—(C₁–C₆)alkoxy, —C(═O)-aryloxy,—C(═S)—(C₁–C₆)alkyl or —C(═S)-aryl; to a compound of formula (I), whereR¹ represents NHR⁴, wherein R⁴ represents —C(═S)—R^(4b), wherein R^(4b)represents (C₁–C₆)alkyl, halo(C₁–C₆)alkyl, —C(═O)—(C₁–C₆)alkoxy,—C(═O)-aryloxy, —C(═S)—(C₁–C₆)alkyl or —C(═S)-aryl; may be carried outby taking a solution of the amide and Lawesson's reagent(2,4-bis(methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) indry dioxane, toluene, THF, DMF and the like. The reaction may be carriedat a temperature in the range of room temperature to 130° C., preferablyat a temperature in the range of 55 to 90° C. The reaction time mayrange from 3 to 24 h, preferably from 3 to 10 h.

In another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where R¹represents NHR⁴, wherein R⁴ represents —C(═S)—SR^(4c), wherein R^(4c)represents (C₁–C₆)alkyl group; from compound of formula (I) where R¹represents NHR⁴ wherein R⁴ represents hydrogen atom,

where all other symbols are as defined earlier.

The compound of formula (I), where R¹ represents NHR⁴, wherein R⁴represents —C(═S)—SR^(4c), wherein R^(4c) represents (C₁–C₆)alkyl group,may be prepared from compound of formula (I) where R¹ represents NHR⁴wherein R⁴ represents hydrogen atom, by using CS₂ in the presence of abase such as Et₃N, diisopropyl ethylamine, K₂CO₃, NaH, KOt-Bu and thelike, followed by the appropriate alkylhalide such as methyliodide,ethylbromide, propylbromide and the like. The reaction may be carriedout in the presence of a solvent such as water, ethanol, methanol,isopropanol, CH₃CN and the like, or mixtures thereof. The reaction maybe carried at a temperature in the range of room temperature to 60° C.,preferably at room temperature. The reaction time may range from 6 to 24h.

In another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where R¹represents NHR⁴, wherein R⁴ represents —C(═S)—OR^(4d), R^(4d) represents(C₁–C₆)alkyl, cyclo(C₃–C₆)alkyl, —(C═O)—(C₁–C₆)alkyl group substitutedwith fluorine; aryl, halo(C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl,(C₁–C₆)alkoxy(C₁–C₆)alkyl or (C₂–C₆) alkenyl, which comprises:

(i) converting the compound of formula (I) where R¹ represents NHR⁴wherein R⁴ represents hydrogen atom, to a compound of formula (I) whereR¹ represents isothiocyanate group,

where all other symbols are as defined earlier,

(ii) converting the compound of formula (I) where R¹ representsisothiocyanate group, to a compound of formula (I) where R¹ representsNHR⁴, wherein R⁴ represents —C(S)—OR^(4d), wherein R^(4d) represents(C₁–C₆)alkyl, cyclo(C₃–C₆)alkyl, —(C═O)—(C₁–C₆)alkyl group substitutedwith fluorine; aryl, halo(C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl,(C₁–C₆)alkoxy(C₁–C₆)alkyl or (C₂–C₆)alkenyl group and all other symbolsare as defined earlier.

The compound of formula (I) where R¹ represents isothiocyanate group,may be prepared from compound of formula (I) where R¹ represents NHR⁴wherein R⁴ represents hydrogen atom, by using thiophosgene, in thepresence of a base such as Et₃N, K₂CO₃, NaOH and the like. The reactionmay be carried out in the presence of a solvent such as ethanol,methanol, isopropanol, CH₂Cl₂, CH₃CN and the like. The reaction may becarried at a temperature in the range of 0 to 60° C., preferably at 0°C. The reaction may be carried out in an inert atmosphere using argon orany other inert gas. The reaction time may range from 3 to 24 h.

The compound of formula (I) where R¹ represents NHR⁴, wherein R⁴represents —C(═S)OR^(4d), wherein R^(4d) represents (C₁–C₆)alkyl,cyclo(C₃–C₆)alkyl, —(C═O)—(C₁–C₆)alkyl group substituted with fluorine;aryl, halo(C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆)alkylor (C₂–C₆)alkenyl, is prepared from the compound of formula (I) where R¹represents isothiocyanate group, by using an alcohol such as methanol,ethanol, propanol, cylcohexanol and the like, in the presence of a basesuch as NaH, KH and the like. The reaction may be carried out in thepresence of a solvent such as THF, toluene, DMF and the like. Thereaction may be carried at a temperature in the range of roomtemperature to 130° C., preferably at reflux temperature of the solventused. The reaction time may range from 6 to 24 h.

In another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where R¹represents NHR⁴, wherein R⁴ represents —C(═S)—N(R′R″), wherein R′represents hydrogen, (C₁–C₆)alkyl, (C₂–C₆)alkenyl, substituted orunsubstituted aralkyl, heteroaralkyl, hydroxy(C₁–C₆)alkyl, R″ representshydrogen or (C₁–C₆)alkyl or the two R′ and R″ groups together form a 5or 6 membered cyclic structures containing one or two hetero atoms; froma compound of formula (I) where R¹ represents isothiocyanate group,

where all other symbols are as defined earlier.

The compound of formula (I), where R¹ represents NHR⁴, wherein R⁴represents —C(═S)—N(R′R″), wherein R′ and R″ independently representhydrogen, is prepared by passing ammonia gas into a solution of compoundof formula (I) where R¹ represents isothiocyanate group, by using asolvent such as THF, toluene, and the like. The reaction may be carriedat a temperature in the range of −10° C. to room temperature, preferablyat −10° C. The reaction time may range from 20 min to 4 h, preferably 30min.

The compound of formula (I), where R¹ represents NHR⁴, wherein R⁴represents —C(═S)—N(R′R″), R¹ represents hydrogen, (C₁–C₆)alkyl,(C₂–C₆)alkenyl, substituted or unsubstituted aralkyl, heteroaralkyl,hydroxy(C₁–C₆)alkyl, R″ represents hydrogen or (C₁–C₆)alkyl or R′ and R″groups together form a 5 or 6 membered cyclic structures containing oneor two hetero atoms, is prepared by treating compound of formula (I)where R¹ represents isothiocyanate group, by using appropriate aminesuch as methylamine, ethylamine, dimethylamine, diethylamine,benzylamine, aniline, proline, morpholine, thiomorpholine,pyridiylmethylamine and the like, in the presence of a solvent such asTHF, DMF, toluene, and the like. The reaction may be carried at atemperature in the range of room temperature to 140° C., preferably at60 to 100° C. The reaction time may range from 1 to 24 h, preferably 4to 12 h.

In yet another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I) where Zrepresents NR^(b) wherein R^(b) represents hydrogen, Y¹ represents ‘═O’group, Y² and Y³ independently represent hydrogen atom, from a compoundof formula (I) where Z represents NR^(b) wherein R^(b) represents(C₁–C₆)alkyl group substituted with hydroxy group, Y¹ represents ‘═Ogroup’, Y² and Y³ independently represent hydrogen atom,

where all other symbols are as defined earlier.

The compound of formula (I) where Z represents NR^(b) wherein R^(b)represents hydrogen, Y¹ represents ‘═O’ group, Y² and Y³ independentlyrepresent hydrogen atom, from a compound of formula (I) wherein Zrepresents NR^(b) wherein R^(b) represents (C₁–C₆)alkyl groupsubstituted with hydroxy group at the α-position, Y¹ represents ‘═Ogroup’, Y² and Y³ independently represent hydrogen atom, may be preparedby treating with a base such as triethylamine, di-isopropylamine,di-isopropylethylamine, pyridine, piperidine, 4-dimethylaminopyridine(DMAP), 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), lithiumdiisopropylamide (LDA), potassium bis-(trimethyl silyl)amide, BuLi,Na₂CO₃, K₂CO₃, NaOH, KOH, NaOMe, NaOEt, NaOiPr, t-BuOK, NaH, KH and thelike. The solvents used in the reaction may be selected from THF, ether,dioxane, toluene, benzene, DMF, DMSO, methylcyanide and the like. Thetemperature of the reaction may be maintained in the range of −20 to150° C., preferably in the range of −10 to 100° C. The duraion of thereaction may be in the range of 0.2 to 64 h, preferably in the range of1 to 48 h.

In still another embodiment of the present invention there is provided aprocess for the preparation of compound of formula (I), where Zrepresents NR^(b) wherein R^(b) represents substituted or unsubstituted(C₁–C₆)alkyl or aralkyl, Y¹ represents ‘═O group’, Y² and Y³independently represent hydrogen atom; from a compound of formula (I)where Z represents NR^(b) wherein R^(b) represents hydrogen, Y¹represents ‘═O’ group, Y² and Y³ independently represent hydrogen atom,

where all other symbols are as defined earlier.

The compound of formula (I), wherein Z represents NR^(b) wherein R^(b)represents substituted or unsubstituted (C₁–C₆)alkyl or aralkyl, Y¹represents ‘═O group’, Y² and Y³ independently represent hydrogen atom,from a compound of formula (I) wherein Z represents NR^(b) wherein R^(b)represents hydrogen, Y¹ represents ‘═O’ group, Y² and Y³ independentlyrepresent hydrogen atom, may be carried out in the presence of a basesuch as triethylamine, di-isopropylamine, di-isopropylethylamine,pyridine, piperidine, DMAP, 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU),lithium diisopropylamide (LDA), potassium bis-(trimethyl silyl)amide,BuLi, Na₂CO₃, K₂CO₃, NaOH, KOH, NaOMe, NaOEt, NaOiPr, t-BuOK, NaH, KHand the like, followed by reacting with alkyl halide such asmethyliodide, methoxymethylchloride, allylbromide, benzylbromide and thelike. The solvent used in the reaction may be selected from DMF, DMSO,THF, dioxane, benzene, toluene and the like. The temperature of thereaction may be maintained in the range of −5 to 150° C., preferably inthe range of 0° C. to reflux temperature of the solvent. The duration ofthe reaction may be in the range of 0.2 to 48 h, preferably in the rangeof 0.5 to 24 h. An alkyl halide or aralkyl halide may also be used.

In another embodiment of the present invention there is provided aprocess for the preparation of a compound of formula (I) where R¹represents halogen, from compound of formula (I) where R¹ representshydroxy group,

where all other symbols are as defined above.

The compound of formula (I) where R¹ represents halogen is prepared fromcompound of formula (I) where Rk represents hydroxy group may be carriedout by treating with a tetrahalomethane group such as CBr₄, CCl₄ or thelike, in the presence of PPh₃, P(alkyl)₃ and the like. The reaction maybe carried out in the presence of a solvent such as dry dichloromethane,chloroform, tetrachloromethane, benzene, DMF, DMSO, THF and the like.The temperature of the reaction may be maintained in the range of 0 to60° C., preferably at room temperature. The duration of the reaction maybe in the range of 2 to 24 h, preferably 8 to 13 h.

In another embodiment of the present invention there is provided aprocess for the preparation of a compound of formula (I) where R¹represents SH, from compound of formula (I) where R¹ represents halogenatom,

where all other symbols are as defined above, which comprises

(i) reacting the compound of formula (I) where R¹ represents halogenatom, to produce a compound of formula (XX),

where all other symbols are as defined earlier, with a base andthioacetic acid,

(ii) reacting the compound of formula (XX), to produce a compound offormula (I) where R¹ represents SH group and all other symbols are asdefined earlier, with base.

The compound of formula (XX) is prepared from compound of formula (I)where R¹ represents hydroxy group is prepared by using thioacetic acidin the presence of a base such as triethylamine, di-isopropylamine,di-isopropylethylamine, pyridine, piperidine, DMAP,1,8-diazabicyclo(5.4.0)undec-7-ene (DBU), lithium diisopropylamide(LDA), potassium bis-(trimethyl silyl)amide, BuLi, Na₂CO₃, K₂CO₃, NaOH,KOH, NaOMe, NaOEt, NaOiPr, t-BuOK, NaH, KH and the like. The solventused in the reaction may be selected from THF, benzene, dioxane and thelike. The temperature of the reaction is maintained in the range of roomtemperature to reflux temperature, preferably at reflux temperature. Theduration of the reaction is maintained in the range of 2 to 24 h,preferably 6 h.

The compound of formula (I), where R¹ represents SH group is preparedfrom compound of formula (XX) by reacting with a base such as K₂CO₃,NaOH, KOH, BuLi or the like. The reaction may be carried out at atemperature in the range of room temperature to reflux temprature. Theduration of the reaction may be in the range of 1 to 24 h.

In still another embodiment of the present invention there is provided anovel intermediate of the formula (VII)

wherein R^(c) represents (C₁–C₈)alkyl group such as methyl, ethyl,propyl, benzyl, allyl group and the like; R² and R³ may be same ordifferent and independently represent hydrogen, halogen atom,(C₁–C₆)alkyl group, halo(C₁–C₆)alkyl, cyano, nitro, SR^(a), NR^(a), orOR^(a) where R^(a) represents substituted or unsubstituted (C₁–C₆)alkylgroup, or halo(C₁–C₆)alkyl; Z represents S, O, ═CH or NR^(b) where R^(b)represents hydrogen or substituted or unsubstituted (C₁–C₆)alkyl,(C₂–C₆)alkenyl, (C₁–C₆)cycloalkyl, (C₁–C₆)alkoxy, aryl, aralkyl,aryloxy, (C₁–C₆)alkylcarbonyl, arylcarbonyl, (C₁–C₆)alkoxycarbonyl oraryloxycarbonyl; Y¹ represents ═O or ═S group; Y² and Y³ independentlyrepresent hydrogen, halogen, cyano, nitro, formyl, hydroxy, amino, ═O,═S group or substituted or unsubstituted groups selected from(C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆)alkyl,(C₁–C₆)alkoxycarbonyl, carboxy(C₁–C₆)alkyl, (C₁–C₆)alkylsulfonyl,(C₁–C₆)alkylcarbonylamino(C₁–C₆)alkyl, arylcarbonylamino(C₁–C₆)alkyl,(C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl, amino(C₁–C₆)alkyl,mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino, arylamino, (C₁–C₆)alkoxy,aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl orheterocycloalkyl; Y² and Y³ when present on adjacent carbon atomstogether may also form a substituted or unsubstituted 5 or 6 memberedaromatic or non-aromatic cyclic structure, optionally containing one ortwo hetero atoms.

The novel intermediate of formula (VII) may be prepared by a process,which comprises:

(i) reacting a compound of formula (III)

where all the symbols are as defined earlier, with a compound of formula(IV)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; R² and R³ are as defined earlier, toproduce a compound of formula (V)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(ii) reducing the compound of formula (V) to produce a compound offormula (VI)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(iii) reacting the compound of formula (VI) with alkylchloroformate, toproduce a compound of formula (VII)

where R^(c), Y¹, Y², Y³ R², R³ and Z are as defined above,

The reaction of a compound of formula (III) with a compound of formula(IV) to produce a compound of formula (V) may be carried out using abase such as KOH, NaOH, K₂CO₃, Na₂CO₃, NaH, KH, triethylamine,diisopropylethyl amine and the like. The reaction may be carried outusing a solvent such as DMSO, DMF, THF, acetonitrile, chloroform and thelike or mixtures thereof. The reaction may be carried out in inertatmosphere, which may be maintained using inert gases such as N₂ or Ar.The reaction may be carried out at a temperature in the range of 20°C.–100° C., preferably at a temperature in the range of ambient to 80°C. The reaction time may range from 1 to 15 h, preferably from 6 to 12h.

The reduction of a compound of formula (V) to produce a compound offormula (VI) may be carried out in the presence of gaseous hydrogen anda catalyst such as Ru, Pd, Rh, Pt, Ni on solid beads such as charcoal,alumina, asbestos and the like. The reduction may be conducted in thepresence of a solvent such as dioxane, acetic acid, ethyl acetate, THF,alcohol such as methanol, ethanol and the like or mixtures thereof. Apressure between atmospheric pressure to 60 psi may be used. Thereaction may be carried out at a temperature from 25 to 60° C.,preferably at room temperature. The reaction time ranges from 2 to 48 h.The reduction may also be carried out by employing metal in mineralacids such Sn/HCl, Fe/HCl, Zn/HCl, Zn/CH₃CO₂H and the like.

The conversion of compound of formula (VI) to compound of formula (VII)may be carried out with an alkylchloroformate such asmethychloroformate, ethylchloroformate, propylchloroformate,benzylchloroformate and the like. The solvent of the reaction may beselected from water, acetone, tetrahydrofuran (THF), acetonitrile,dichloromethane (DCM) and the like or mixtures thereof. The reaction maybe carried out in the presence of base such as K₂CO₃, Na₂CO₃, NAH, KOH,triethylamine and the like. The temperature of the reaction may becarried out in the presence of 0 to 60° C., preferably at 0° C. to roomtemperature. The time of the reaction is maintained in the range of 1–12h, preferably in the range of 1–4 h.

In still another embodiment of the present invention there is provided anovel intermediate of formula (VI)

where R² and R³ may be same or different and independently representhydrogen, halogen atom, (C₁–C₆)alkyl group, halo(C₁–C₆)alkyl, cyano,nitro, SR^(a), NR^(a), or OR^(a) where R^(a) represents substituted orunsubstituted (C₁–C₆)alkyl group, or halo(C₁–C₆)alkyl; Z represents S,O, ═CH or NR^(b) where R^(b) represents hydrogen or substituted orunsubstituted (C₁–C₆)alkyl, (C₂–C₆)alkenyl, (C₁–C₆)cycloalkyl,(C₁–C₆)alkoxy, aryl, aralkyl, aryloxy, (C₁–C₆)alkylcarbonyl,arylcarbonyl, (C₁–C₆)alkoxycarbonyl or aryloxycarbonyl; Y¹ represents ═Oor ═S group; Y² and Y³ independently represent hydrogen, halogen, cyano,nitro, formyl, hydroxy, amino, ═O, ═S group or substituted orunsubstituted groups selected from (C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl,(C₁–C₆)alkoxy(C₁–C₆)alkyl, (C₁–C₆)alkoxycarbonyl, carboxy(C₁–C₆)alkyl,(C₁–C₆)alkylsulfonyl, (C₁–C₆)alkylcarbonylamino(C₁–C₆)alkyl,arylcarbonylamino(C₁–C₆)alkyl, (C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl,amino(C₁–C₆)alkyl, mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino,arylamino, (C₁–C₆)alkoxy, aryl, aryloxy, aralkyl, heteroaryl,heteroaralkyl, heterocyclyl or heterocycloalkyl; any two of Y² and Y³when present on adjacent carbon atoms together may also form asubstituted or unsubstituted 5 or 6 membered aromatic or non-aromaticcyclic structure, optionally containing one or two hetero atoms.

The novel intermediate of formula (VI) may be prepared by a process,which comprises:

(i) reacting a compound of formula (III)

where all the symbols are as defined earlier, with a compound of formula(IV)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; R² and R³ are as defined earlier, toproduce a compound of formula (V)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier, and

(ii) reducing the compound of formula (V) to produce a compound offormula (VI)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier.

The reaction of a compound of formula (III) with a compound of formula(IV) to produce a compound of formula (V) may be carried out using abase such as KOH, NaOH, K₂CO₃, Na₂CO₃, NaH, KH, triethylamine,diisopropylethyl amine and the like. The reaction may be carried outusing a solvent such as DMSO, DMF, THF, acetonitrile, chloroform and thelike or mixtures thereof. The reaction may be carried out in inertatmosphere, which may be maintained using inert gases such as N₂ or Ar.The reaction may be carried out at a temperature in the range of 20°C.–100° C., preferably at a temperature in the range of ambient to 80°C. The reaction time may range from 1 to 15 h, preferably from 6 to 12h.

The reduction of a compound of formula (V) to produce a compound offormula (VI) may be carried out in the presence of gaseous hydrogen anda catalyst such as Ru, Pd, Rh, Pt, Ni on solid beads such as charcoal,alumina, asbestos and the like. The reduction may be conducted in thepresence of a solvent such as dioxane, acetic acid, ethyl acetate, THF,alcohol such as methanol, ethanol and the like or mixtures thereof. Apressure between atmospheric pressure to 60 psi may be used. Thereaction may be carried out at a temperature from 25 to 60° C.,preferably at room temperature. The reaction time ranges from 2 to 48 h.The reduction may also be carried out by employing metal in mineralacids such Sn/HCl, Fe/HCl, Zn/HCl, Zn/CH₃CO₂H and the like.

In yet another embodiment of the present invention there is provided anovel intermediate of formula (X)

wherein R¹ represents halo, azido, thioalcohol, isothiocyanate, OR⁴,NHR⁴ or N(R⁴)₂, where R⁴ represents hydrogen atom, or substituted orunsubstituted groups selected from acyl, thioacyl,(C₁–C₆)alkoxycarbonyl, (C₃–C₆)cycloalkoxythiocarbonyl,(C₂–C₆)alkenyloxycarbonyl, (C₂–C₆)alkenylcarbonyl, aryloxycarbonyl,(C₁–C₆)alkoxythiocarbonyl, (C₂–C₆)alkenyloxythiocarbonyl,aryloxythiocarbonyl, —C(═O)—C(═O)-alkyl, —C(═O)—C(═O)-aryl,—C(═O)—C(═O)-alkoxy, —C(═O)—C(═O)-aryloxy, —(C═S)—S-alkyl, —(C═S)—NH₂,—(C═S)—NH-alkyl, —C(═S)—N-(alkyl)₂, —C(═S)—NH-alkenyl,(C═S)—(C═O)-alkoxy, —(C═S)—(C═O)-aryloxy, —C(═S)—O—(C═O)-alkyl,C(═S)—C(═S)-alkyl, —C(═S)—C(═S)-aryl, thiomorpholinylthiocarbonyl orpyrrolidinylthiocarbonyl; R² and R³ may be same or different andindependently represent hydrogen, halogen atom, (C₁–C₆)alkyl group,halo(C₁–C₆)alkyl, cyano, nitro, SR^(a), NR^(a), OR^(a) where R^(a)represents substituted or unsubstituted (C₁–C₆)alkyl group, orhalo(C₁–C₆)alkyl; Z represents S, O, ═CH or NR^(b) where R^(b)represents hydrogen or substituted or unsubstituted (C₁–C₆)alkyl,(C₂–C₆)alkenyl, (C₁–C₆)cycloalkyl, (C₁–C₆)alkoxy, aryl, aralkyl,aryloxy, (C₁–C₆)alkylcarbonyl, arylcarbonyl, (C₁–C₆)alkoxycarbonyl oraryloxycarbonyl; Y¹ represents ═O or ═S group and Y² or Y³ representshydrogen, halogen, cyano, nitro, formyl, hydroxy, amino, ═O, ═S group orsubstituted or unsubstituted groups selected from (C₁–C₆)alkyl,hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆)alkyl, (C₁–C₆)alkoxycarbonyl,carboxy(C₁–C₆)alkyl, (C₁–C₆)alkylsulfonyl,(C₁–C₆)alkylcarbonylamino(C₁–C₆)alkyl, arylcarbonylamino (C₁–C₆)alkyl,(C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl, amino(C₁–C₆)alkyl, mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino, arylamino, (C₁–C₆)alkoxy, aryl,aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl orheterocycloalkyl; Y² and Y³ when present on adjacent carbon atomstogether may also form a substituted or unsubstituted 5 or 6 memberedaromatic or non-aromatic cyclic structure, optionally containing one ortwo hetero atoms.

The novel intermediate of formula (X) may be prepared by a process,which comprises:

(i) reacting a compound of formula (III)

where all the symbols are as defined earlier, with a compound of formula(IV)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; R² and R³ are as defined earlier, toproduce a compound of formula (V)

where Y¹, Y², Y³, R², R³ and Z are as defined earlier,

(ii) reducing the compound of formula (V) to produce a compound offormula (VI)

where Y¹, Y¹, Y³, R², R³ and Z are as defined earlier, and

(iii) reacting the compound of formula (VI) with a compound of formula(IX)

where R¹ represents NHR⁴ or N(R⁴)₂, where R⁴ represents hydrogen atom,or substituted or unsubstituted groups selected from acyl, thioacyl,(C₁–C₆)lkoxycarbonyl, (C₃–C₆)cycloalkoxythiocarbonyl,(C₂–C₆)alkenyloxycarbonyl, (C₂–C₆)alkenylcarbonyl, aryloxycarbonyl,(C₁–C₆)alkoxythiocarbonyl, (C₂–C₆) lkenyloxythiocarbonyl,aryloxythiocarbonyl, —C(═O)—C(═O)-alkyl, —C(═O)—C(═O)-aryl,—C(═O)—C(═O)-alkoxy, —C(═O)—C(═O)-aryloxy, —(C═S)—S-alkyl, —(C═S)—NH₂,—(C═S)—NH-alkyl, —C(═S)—N-(alkyl)₂, —C(═S)—NH-alkenyl,(C═S)—(C═O)-alkoxy, —(C═S)—(C═O)-aryloxy, —C(═S)—O—(C═O)-alkyl,C(═S)—C(═S)-alkyl, —C(═S)—C(═S)-aryl, thiomorpholinylthiocarbonyl orpyrrolidinylthiocarbonyl, to produce a compound of formula (X)

where Y¹, Y², Y³, R², R³ and Z are as defined above.

The reaction of a compound of formula (III) with a compound of formula(IV) to produce a compound of formula (V) may be carried out using abase such as KOH, NaOH, K₂CO₃, Na₂CO₃, NaH, KH, triethylamine,diisopropylethyl amine and the like. The reaction may be carried outusing a solvent such as DMSO, DMF, THF, acetonitrile, chloroform and thelike or mixtures thereof. The reaction may be carried out in inertatmosphere, which may be maintained using inert gases such as N₂ or Ar.The reaction may be carried out at a temperature in the range of 20°C.–1 00° C., preferably at a temperature in the range of ambient to 80°C. The reaction time may range from 1 to 15 h, preferably from 6 to 12h.

The reduction of a compound of formula (V) to produce a compound offormula (VI) may be carried out in the presence of gaseous hydrogen anda catalyst such as Ru, Pd, Rh, Pt, Ni on solid beads such as charcoal,alumina, asbestos and the like. The reduction may be conducted in thepresence of solvents such as dioxane, acetic acid, ethyl acetate, THF,alcohol such as methanol, ethanol and the like or mixtures thereof. Apressure between atmospheric pressure to 60 psi may be used. Thereaction may be carried out at a temperature from 25 to 60° C.,preferably at room temperature. The reaction time ranges from 2 to 48 h.The reduction may also be carried out by employing metal in mineralacids such Sn/HCl, Fe/HCl, Zn/HCl, Zn/CH₃CO₂H and the like.

The reaction of a compound of formula (VI) defined above with a compoundof formula (IX) defined above to produce a compound of formula (X) maybe carried out in the presence or absence of a base such as K₂CO₃, NaH,t-BuOK and the like or mixtures thereof. The reaction may be carried outin the presence of a solvent such as toluene, DMF, THF, or CH₃CN. Thereaction may also be carried out in the presence of Lewis acids such asBF₃.OEt₂, ZnCl₂, Ti(OiPr)₄ lanthanide metal complexes and the like inthe presence of DCE, DMF, THF or the like or mixtures thereof. Thereaction temperature may be in the range of 0 to 120° C., preferably ata temperature in the range of 0 to 100° C. The reaction time may rangefrom 3 to 24 h, preferably from 4 to 12 h.

In yet another embodiment of the present invention there is provided anovel intermediate of formula (XVI)

where R^(c) represents (C₁–C₈)alkyl group such as methyl, ethyl, propyl,benzyl, allyl group and the like; R² and R³ may be same or different andindependently represent hydrogen, halogen atom, (C₁–C₆)alkyl group,halo(C₁–C₆)alkyl, cyano, nitro, SR^(a), NR^(a), OR^(a) where R^(a)represents substituted or unsubstituted (C₁–C₆)alkyl group, orhalo(C₁–C₆)alkyl; Z represents S, O, ═CH or NR^(b) where R^(b)represents hydrogen or substituted or unsubstituted (C₁–C₆)alkyl,(C₂–C₆)alkenyl, (C₁–C₆)cycloalkyl, (C₁–C₆)alkoxy, aryl, aralkyl,aryloxy, (C₁–C₆)alkylcarbonyl, arylcarbonyl, (C₁–C₆)alkoxycarbonyl oraryloxycarbonyl; Y¹ represents ═O or ═S group and Y² or Y³ representshydrogen, halogen, cyano, nitro, formyl, hydroxy, amino, ═O, ═S group orsubstituted or unsubstituted groups selected from (C₁–C₆)alkyl,hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆)alkyl, (C₁–C₆)alkoxycarbonyl,carboxy(C₁–C₆)alkyl, (C₁–C₆)alkylsulfonyl,(C₁–C₆)alkylcarbonylamino(C₁–C₆)alkyl, arylcarbonylamino(C₁–C₆)alkyl,(C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl, amino(C₁–C₆)alkyl,mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino, arylamino, (C₁–C₆)alkoxy,aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl orheterocycloalkyl; Y² and Y³ when present on adjacent carbon atomstogether may also form a substituted or unsubstituted 5 or 6 memberedaromatic or non-aromatic cyclic structure, optionally containing one ortwo hetero atoms.

The novel intermediate of formula (XVI) may be prepared by a process,which comprises:

(i) reacting a compound of formula (VII)

where all the symbols are as defined earlier, with a compound of formula(XIV)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; to produce a compound of formula (XV)

where R^(c), Y¹, Y², Y³, R², R³ and Z are as defined earlier and

(ii) hydrolysing the acetonide moiety in the compound of formula (XV)using conventional methods to produce a compound of formula (XVI)

where R^(c), Y¹, Y², Y¹, R², R³ and Z are as defined earlier.

The reaction of a compound of formula (VII) with a compound of formula(XIV) to produce a compound of formula (XV) may be carried out in thepresence of a base. The base employed may be selected from K₂CO₃, NaH,t-BuOK, LDA and the like. The reaction may be carried out in thepresence of a solvent such as DMF, THF, DMSO, EtOH and the like. Thereaction may be carried at a temperature in the range of −78 to 120° C.,preferably at a temperature in the range of −78 to 100° C. The reactiontime may range from 2 to 24 h, preferably from 2 to 20 h.

The hydrolysis of a compound of formula (XV) to produce a compound offormula (XVI) may be carried out using dilute mineral acid such as HCl,H₂SO₄ and the like, organic acids such as aqueous acetic acid, p-toluenesulfonic acid, camphor sulfonic acid, trifluoro acetic acid and thelike. The reaction may be carried out in the presence of suitablesolvent such as water, methanol, THF, dioxane and the like or mixturesthereof. The reaction may be carried at a temperature in the range of 30to 100° C., preferably at a temperature in the range of 30 to 60° C. Thereaction time may range from 10 min to 5 h, preferably from 30 min to2.5 h.

In yet another embodiment of the present invention there is provided anovel intermediate of formula (XVIII)

wherein R^(c) represents (C₁–C₈)alkyl group such as methyl, ethyl,propyl, benzyl, allyl group and the like; R² and R³ may be same ordifference and independently represent hydrogen, halogen atom,(C₁–C₆)alkyl group, halo(C₁–C₆)alkyl, cyano, nitro, SR^(a), NR^(a),OR^(a) where R^(a) represents substituted or unsubstituted (C₁–C₆)alkylgroup, or halo(C₁–C₆)alkyl; Z represents S, O, ═CH or NR^(b) where R^(b)represents hydrogen or substituted or unsubstituted (C₁–C₆)alkyl,(C₂–C₆)alkenyl, (C₁–C₆)cycloalkyl, (C₁–C₆)alkoxy, aryl, aralkyl,aryloxy, (C₁–C₆)alkylcarbonyl, arylcarbonyl, (C₁–C₆)alkoxycarbonyl oraryloxycarbonyl; Y¹ represents ═O or ═S group and Y² or Y³ representshydrogen, halogen, cyano, nitro, formyl, hydroxy, amino, ═O, ═S group orsubstituted or unsubstituted groups selected from (C₁–C₆)alkyl,hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆)alkyl, (C₁–C₆)alkoxycarbonyl,carboxy(C₁–C₆)alkyl, (C₁–C₆)alkylsulfonyl,(C₁–C₆)alkylcarbonylamino(C₁–C₆)alkyl, arylcarbonylamino(C₁–C₆)alkyl,(C₁–C₆)alkylcarbonyloxy(C₁–C₆)alkyl, amino(C₁–C₆)alkyl,mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino, arylamino, (C₁–C₆)alkoxy,aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl orheterocycloalkyl; Y² and Y³ when present on adjacent carbon atomstogether may also form a substituted or unsubstituted 5 or 6 memberedaromatic or non-aromatic cyclic structure, optionally containing one ortwo hetero atoms.

The novel intermediate of formula (XVIII) may be prepared by a process,which comprises: reacting a compound of formula (VII)

where all the symbols are as defined earlier, with a compound of formula(XVII)

where L represents a leaving group such as halogen atom, alkoxy,sulfonyl groups and the like; to produce a compound of formula (XVIII)

where R^(c), Y¹, Y², Y³, R², R³ and Z are as defined earlier.

The reaction of a compound of formula (VII) defined above with acompound of formula (XVII) defined above may be carried out in thepresence of a base such as NaH, NaOMe, K₂CO₃, n-BuLi, LDA and the like.The reaction may be carried out in the presence of a solvent such asDMF, THF, DMSO, benzene and the like or mixtures thereof. The reactionmay be carried out at a temperature in the range of −78 to 70° C.preferably at a temperature in the range of −78 to 50° C. The reactiontime may range from 1 to 15 h preferably 1 to 10 h.

It is appreciated that in any of the above-mentioned reactions, anyreactive group in the substrate molecule may be protected according toconventional chemical practice. Suitable protecting groups in any of theabove mentioned reactions are tertiarybutyldimethylsilyl, methoxymethyl,triphenyl methyl, benzyloxycarbonyl, tetrahydropyran(THP) etc, toprotect hydroxyl or phenolic hydroxy group; N-tert-butoxycarbonyl(N-Boc), N-benzyloxycarbonyl (N-Cbz), N-9-fluorenyl methoxy carbonyl(N-FMOC), benzophenoneimine, propargyloxy carbonyl (POC) etc, forprotection of amino or anilino group, acetal protection for aldehyde,ketal protection for ketone and the like. The methods of formation andremoval of such protecting groups are those conventional methodsappropriate to the molecule being protected.

The enantiomers may be prepared by using reactants in their singleenantiomeric form in the process wherever applicable or by conductingthe reaction in the presence of reagents or catalysts in their singleenantiomeric form. The single enantiomers may also be prepared byresolving the racemic mixture by conventional methods. The stereoisomersof the compounds forming part of this invention may be prepared by usingreactants in their single enantiomeric form in the process whereverpossible or by conducting the reaction in the presence of reagents orcatalysts in their single enantiomer form or by resolving the mixture ofstereoisomers by conventional methods. Some of the preferred methodsinclude use of microbial resolution, resolving the diastereomeric saltsformed with chiral acids such as mandelic acid, camphorsulfonic acid,tartaric acid, lactic acid, and the like wherever applicable or chiralbases such as brucine, cinchona alkaloids and their derivatives and thelike. Commonly used methods are compiled by Jaques et al in“Enantiomers, Racemates and Resolution” (Wiley Interscience, 1981).Where appropriate the compounds of formula (I) may be resolved bytreating with chiral amines, aminoacids, aminoalcohols derived fromaminoacids; conventional reaction conditions may be employed to convertacid into an amide; the diastereomers may be separated either byfractional crystallization or chromatography and the stereoisomers ofcompound of formula (I) may be prepared by hydrolyzing the purediastereomeric amide.

The pharmaceutically acceptable salts are prepared by reacting thecompounds of formula (I) wherever applicable with 1 to 4 equivalents ofa base such as sodium hydroxide, sodium methoxide, sodium hydride,potassium t-butoxide, calcium hydroxide, magnesium hydroxide and thelike, in solvents like ether, THF, methanol, t-butanol, dioxane,isopropanol, ethanol etc. Mixture of solvents may be used. Organic baseslike lysine, arginine, diethanolamine, choline, tromethamine, guanidineand their derivatives etc., may also be used. Alternatively, acidaddition salts wherever applicable are prepared by treatment with acidssuch as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid,phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, aceticacid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid,ascorbic acid, palmitic acid, succinic acid, benzoic acid,benzenesulfonic acid, tartaric acid and the like in solvents like ethylacetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solventsmay also be used. The salts of amino acid groups and other groups may beprepared by reacting the compounds of formula (I) with the respectivegroups in solvents like alcohols, ketones, ether etc. Mixture ofsolvents may be used.

Various polymorphs of a compound of general formula (I) forming part ofthis invention may be prepared by crystallization of compound of formula(I) under different conditions. For example, using different solventscommonly used or their mixtures for recrystallization; crystallizationsat different temperatures; various modes of cooling, ranging from veryfast to very slow cooling during crystallizations. Heating or meltingthe compound followed by gradual or fast cooling may also obtainpolymorphs. The presence of poly-morphs may be determined by solid probenmr spectroscopy, IR spectroscopy, differential scanning calorimetry,powder X-ray diffraction or such other techniques.

The present invention also provides pharmaceutical compositions,containing compounds of the general formula (I), as defined above, theirderivatives, their analogs, their tautomeric forms, their stereoisomers,their polymorphs, their pharmaceutically acceptable salts or theirpharmaceutically acceptable solvates in combination with the usualpharmaceutically employed carriers, diluents and the like. Thepharmaceutical compositions according to this invention can be used forthe treatment of bacterial infections. They can also be used for thetreatment of bacterial infections associated with multidrug resistance.Pharmaceutically acceptable solvates of compound of formula (I) formingpart of this invention may be prepared by conventional methods such asdissolving the compounds of formula (I) in solvents such as water,methanol, ethanol etc., preferably water and recrystallizing by usingdifferent crystallization techniques.

The pharmaceutical compositions may be in the forms normally employed,such as tablets, capsules, powders, syrups, solutions, suspensions andthe like, may contain flavorants, sweeteners etc., in suitable solid orliquid carriers or diluents, or in suitable sterile media to forminjectable solutions or suspensions. Such compositions typically containfrom 1 to 20%, preferably 1 to 10% by weight of active compound, theremainder of the composition being pharmaceutically acceptable carriers,diluents or solvents.

Suitable pharmaceutically acceptable carriers include solid fillers ordiluents and sterile aqueous or organic solutions. The active compoundswill be present in such pharmaceutical compositions in the amountssufficient to provide the desired dosage in the range as describedabove. Thus, for oral administration, the compounds can be combined witha suitable solid, liquid carrier or diluent to form capsules, tablets,powders, syrups, solutions, suspensions and the like. The pharmaceuticalcompositions, may, if desired, contain additional components such asflavorants, sweeteners, excipients and the like. For parenteraladministration, the compounds can be combined with sterile aqueous ororganic media to form injectable solutions or suspensions. For example,solutions in sesame or peanut oil, aqueous propylene glycol and the likecan be used, as well as aqueous solutions of water-solublepharmaceutically-acceptable acid addition salts or salts with base ofthe compounds. The injectable solutions prepared in this manner can thenbe administered intravenously, intraperitoneally, subcutaneously, orintramuscularly, with intramuscular administration being preferred inhumans.

In addition to the compounds of formula (I) the pharmaceuticalcompositions of the present invention may also contain or beco-administered with one or more known drugs selected from otherclinically useful antibacterial agents such as β-lactams oraminoglycosides. These may include penicillins such as oxacillin orflucloxacillin and carbapenems such as meropenem or imiphenem to broadenthe therapeutic effectiveness against, for example,methicillin-resistant staphylococci. Compounds of the formula (I) of thepresent invention may also contain or be co-admistered withbactericidal/permeability-increasing protein product (BPI) or effluxpump inhibitors to improve activity against gram negative bacteria andbacteria resistant to antimicrobial agents.

The compounds of the formula (I) as defined above are clinicallyadministered to mammals, including human beings, via either oral orparenteral routes. Administration by the oral route is preferred, beingmore convenient and avoiding the possible pain and irritation ofinjection. However, in circumstances where the patient cannot swallowthe medication, or absorption following oral administration is impaired,as by disease or other abnormality, it is essential that the drug beadministered parenterally. By either route, the dosage is in the rangeof about 5 mg/kg to about 20 mg/kg body weight of the subject per dayadministered singly or as a divided dose. However, the optimum dosagefor the individual subject being treated will be determined by theperson responsible for treatment, generally smaller doses beingadministered initially and thereafter increments made to determine themost suitable dosage.

The invention is explained in detail in the examples given below whichare provided by way of illustration only and therefore should not beconstrued to limit the scope of the invention.

General Procedure for Preparations 1–9

A mixture of appropriate nitro compound such as 4-fluoronitrobenzene andthe like, appropriate heterocycle such as oxazolidinone or itsequivalents (1.1 eq) (An equivalent derivative of 2-oxazolidinone is afive membered heterocyclic group containing two heteroatoms selectedfrom oxygen, nitrogen, and sulfur; and substituted by an ═O or ═S group,the heterocycle may be fused with substituted or unsubstituted phenylgroup) and anhydrous K₂CO₃ (2.0 eq) in dry DMF was stirred attemperature ranging from 0 to 100° C. (depending on the substrate)overnight. Cold water was added to the reaction mixture and the solidformed was filtered. The filtered solids were dried to yield purecompound. Yield: 50–85%.

S. No. Preparation Analystical data 1

¹HNMR (CDCl₃, 200MHz): δ 8.25(d, J=9.2Hz, 2H), 7.72(d, J=9.2Hz,2H),4.57(t, J=7.3Hz, 2H), 4.18(t,J=7.3Hz, 2H).Mass (CI method): 209. 2

¹HNMR (CDCl₃, 200MHz): δ 8.12–7.93(m, 3H), 4.56(t, J=7.3Hz, 2H),4.23(t,J=7.3Hz, 2H).Mass (CI method): 227. 3

¹HNMR (CDCl₃, 200MHz): δ 7.92(d, J=7.8Hz, 2H), 4.64(t, J=7.4Hz,2H),4.07(t, J=7.4Hz, 2H).Mass (CI method): 245, 215. 4

¹HNMR (CDCl₃, 200MHz): δ 8.00(m, 1H), 7.15(m, 2H), 4.56(t, J=7.4Hz, 2H),4.06(t, J=7.4Hz, 2H).Mass (CI method): 226, 180, 164,152, 135, 109, 94.5

¹HNMR (CDCl₃, 200MHz): δ 8.64–8.48(m, 2H), 7.69(d, J=8.8Hz, 1H),4.60(t,J=7.3Hz, 2H), 4.01(t, J=7.3Hz, 2H).Mass (CI method): 276, 232, 217,171,144. 6

¹HNMR (CDCl₃, 200MHz): δ 8.14–8.04(m, 2H), 7.90(t, J=7.6Hz, 1H),4.76(t,J=8.4Hz, 2H), 4.23(t, J=8.4Hz, 2H).Mass (CI method): 242, 223, 167,121,94. 7

¹HNMR (CDCl₃, 200MHz): δ 8.14–8.07(m, 2H), 7.72(t, J=7.6Hz, 1H),4.43(t,J=7.6Hz, 2H), 3.57(t, J=7.6Hz, 2H).Mass (CI method): 258, 239, 212,193,108. 8

¹HNMR (CDCl₃, 200MHz): δ 8.11–8.02(m, 2H), 7.96(t, J=7.8Hz,1H),4.09–3.83(2t, 4H), 3.27(s, 2H).Mass (CI method): 255, 236, 209, 190.9

¹HNMR (CDCl₃, 200MHz): δ 8.23(m, 2H), 7.81(t, J=7.4Hz, 1H), 7.22(t,J=7.4Hz, 1H), 7.03(d, J=8.4Hz,1H).Mass (CI method): 288, 258, 243,197,94.

A solution of 4-fluoronitrobenzene (5 g, 35.4 mmol) in CH₃CN (250 ml)was stirred at room temperature under argon overnight. The reactionmixture was filtered and the filtrate was concentrated. The residueobtained was suspended in pet. ether and filtered. The solids werecollected to afford the nitro compound (4.1 g, 64%) as yellow crystals.

¹H NMR (DMSO+CDCl₃, 200 MHz): δ 7.97 (d, J=9.3 Hz, 2H), 7.09 (bs, 1H),6.62 (d, J=9.3 Hz, 2H), 2.80–3.40 (m, 6H). Mass(CI method): 181, 152,135, 105.

Preparation 11 1-(4-Nitrophenyl)-2-imidazolidinone

A solution of phosgene (20% in toluene, 13 ml, 26.5 mmol) in toluene wasadded drop wise to a solution of the diamine (4 g, 22 mmol) (obtained inpreparation 10) and Et₃N (7.6 ml, 55 mmol) in dichloromethane (100 ml)at 0° C. under argon. After being stirred at same temperature for 1 h,the reaction mixture was poured in water and extracted withdichloromethane (4×150 ml). The combined organic extracts were washedwith water, brine and dried. The residue obtained upon evaporation ofthe solvents was passed through a column of silica gel to afford theproduct (3 g, 66%) as yellow solid.

¹H NMR (CDCl₃, 200 MHz): δ 8.17 (d, J=9.3 Hz, 2H), 7.75 (d, J=9.2 Hz,2H), 7.07 (bs, 1H), 4.00 (t, J=8.8 Hz, 2H), 3.59 (t, J=8.8 Hz, 2H).Mass(CI method): 207, 151, 105.

Preparation 12 1-Methyl-3-(4-nitrophenyl)-2-imidazolidinone

Sodium hydride (60% in oil, 138 mg, 5.3 mmol) was added portion wise toa solution of the nitro compound (1 g, 4.8 mmol) (obtained inpreparation 11) in dry DMF (15 ml) under argon at 0° C. Stirred thereaction mixture at the same temperature for 15 min. Methyl iodide (MeI)(0.68 g, 4.8 mmol) was added and the reaction mixture was stirred for 1h. Ice pieces were added to the reaction mixture and the solid formedwas filtered to afford the product (900 mg, 84%) as yellow crystals.

¹H NMR (CDCl₃, 200 MHz): δ 8.19 (d, J=9.3 Hz, 2H), 7.70 (d, J=9.3 Hz,2H), 3.88 (t, J=8.8 Hz, 2H), 3.54 (t, J=8.8 Hz, 2H), 2.93 (s, 3H).Mass(CI method): 222.

Preparation 13 1-(3-Fluoro-4-nitrophenyl)-4-imidazolidinone

A solution of 4-imidazolidinone (9.5 g, 110.5 mmol),3,4-difluoronitrobenzene (12.2 ml, 110.5 mmol) and diisopropylethylamine (28.6 ml, 165 mmol) in dry DMF (80 ml) was heated to 60° C.overnight under argon. The reaction mixture was allowed to cool to roomtemperature and ice pieces were added. The solid formed was filtered andwashed with water. The solid was dried under air to yield the nitrocompound (19.5 g, 78.5%) as yellow crystals.

¹H NMR (DMSO, 200 MHz): δ 8.81 (bs, 1H), 8.07–7.96 (m, 2H), 6.82 (t,J=8.8 Hz, 1H), 4.97 (s, 2H), 4.06 (s, 2H). Mass (CI method): 226, 185,152.

Preparation 14 N1-phenyl-2-azidoacetamide

Chloroacetyl chloride (5.1 ml, 64.5 mmol) was added drop wise to asolution of aniline (5 g, 53.7 mmol) and Et₃N (18.7 ml, 134.3 mmol) indichloromethane (150 ml) at 0° C. under argon. After the completion ofreaction (TLC control), the reaction mixture was diluted withdichloromethane (300 ml). The resultant mixture was washed with water,brine and dried. The residue obtained upon evaporation of solvent wastaken up in dry DMF (40 ml), added NaN₃ (6.15 g, 94.6 mmol) and theresultant mixture was stirred at 80° C. for 2 h. The reaction mixturewas diluted with ethyl acetate and washed with water, brine and dried.The residue obtained upon evaporation of the solvent was chromatographedover silica gel to afford the azide (6 g, 63%).

Preparation 15 N1-phenyl-2-(2-fluoro-4-nitroanilino)acetamide

A solution of the azide (6 g, 34 mmol) obtained in preparation 14 wastaken in MeOH (60 ml) and the resultant solution was hydrogenated over10% Pd on charcoal (2.5 g) overnight. The reaction mixture was filteredon a celite pad and the filtrate was concentrated. To this residue dryDMF (40 ml) was added followed by diisopropyl ethyl amine (16.7 ml, 93.8mmol) and 3,4-difluoronitrobenzene (3.8 ml, 37.5 mmol). The resultantsolution was kept at 80° C. overnight with continuous monitoring by TLC.Ice-cold water was added to the reaction mixture and the solid separatedwas filtered to afford the nitro compound as a yellow solid (6 g, 61%).

¹H NMR (DMSO+CDCl₃, 200 MHz): δ 9.74 (bs, 1H), 7.84–8.00 (m, 2H), 7.58(d, J=8.3 Hz, 2H), 7.30 (d, J=8.3 Hz, 2H), 7.08 (m, 1H), 6.66 (t, J=8.8Hz, 1H), 6.45 (bs, 1H), 4.09 (d, J=5.4 Hz, 2H). Mass (CI Method): 290.

Preparation 16 N1-(2-anilinoethyl)-2-fluoro-4-nitroaniline

A 1 M solution of BH₃.THF (45 ml, 45 mmol) was added drop wise to asolution of the nitro compound (4.5 g, 15.5 mmol) (obtained inpreparation 15) in dry THF (30 ml) at 0° C. under argon. The reactionmixture was stirred overnight at room temperature and then water wasadded cautiously to quench the excess borane. The volatiles were removedfrom the reaction mixture under vacuum and the residue was taken up inethyl acetate (400 ml). The organic layer was washed with water, brineand dried. The residue obtained upon evaporation of the solvent waspassed through column to afford the product (4 g, 93%).

¹H NMR (CDCl₃, 200 MHz): δ 8.02–7.86 (m, 2H), 7.26–7.18 (m, 2H),6.82–6.62 (m, 4H), 4.94 (bs, 1H), 3.83 (bs, 1H), 3.51 (s, 4H). Mass (CImethod): 274.

Preparation 17 1-(2-Fluoro-4-nitrophenyl)-3-phenyl-2-imidazolidinone

A solution of phosgene (20% in toluene, 7.4 ml, 14.7 mmol) was addeddrop wise to a solution of the diamine (4 g, 14.5 mmol) (obtained inpreparation 16) and Et₃N (5.6 ml, 40.4 mmol) in dichloromethane (50 ml)at 0° C. under argon. Stirred for 2 h at the same temperature thereaction mixture was diluted with dichloromethane (300 ml) and washedwith water, brine and dried. The crystals obtained upon evaporation ofthe solvents were suspended in petroleum ether and filtered. The productwas isolated as yellow crystals (4 g, 91.4%).

¹H NMR (CDCl₃, 200 MHz): δ 8.10–7.11 (m, 8H), 4.22–4.00 (m, 4H). Mass(CI Method): 302, 106.

Preparation 181-(2-Fluoro-4-nitrophenyl)-3-hydroxymethyl-4-imidazolidinone

A mixture of 1-(3-fluoro-4-nitrophenyl)-4-imidazolidinone (9 g, 40 mmol)(obtained in preparation 13) and 40% solution of formaldehyde (100 mL)was heated to reflux for 4 h. The reaction mixture was allowed to coolto room temperature and ice water mixture was added. The precipitatedsolid was filtered and dried to give the product as yellow solid (8.5 g,83% yield).

¹H NMR (DMSO-d⁶, 200MHz): δ 8.10–7.95 (m, 2H), 6.90–6.80 (m, 1H), 6.20(t, J=6.8 Hz, 1H), 5.13 (d, J=2.9 Hz, 2H), 4.77 (d, J=7.3 Hz, 2H), 4.19(s, 2H).

Mass (CI method): 226.

Preparation 191-(2-Fluoro-4-nitrophenyl)-3-hydroxymethyl-4-imidazolidinone

A solution of1-(2-fluoro-4-nitrophenyl)-3-hydroxymethyl-4-imidazolidinone (6.7 g,26.2 mmol) (obtained in preparation 18), pyridinium p-toluenesulphonate(PPTS) (65 mg, 0.39 mmol) and 3,4-dihydro-2H-pyran (3.6 mL, 39.4 mmol)in dichloromethane (100 mL) was stirred at room temperature under argonovernight. The reaction mixture was diluted with dichloromethane (400mL), washed with half-saturated brine (2×100 mL) and dried. The residueobtained upon evaporation of solvent was passed through a column ofsilica gel to afford the product as yellow solid (7 g, 79%).

¹H NMR (CDCl₃, 200MHz): δ 8.05–7.85 (m, 2H), 6.60–6.45 (m, 1H),5.30–4.70 (m, 5H), 4.17 (s, 2H), 4.20–3.30 (m, 4H), 2.00–1.40 (m, 6H).Mass (CI method): 340, 256, 237.

Preparation 20 General Procedure for the Conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

A solution of the nitro compound in THF was hydrogenated over 10% Pd oncharcoal (catalytic amount) overnight. After the complete consumption ofstarting material, a 5% solution of Na₂CO₃ (2.2 eq) in water was addedfollowed benzyl chloroformate (1.2 eq) at 0° C. After stirring thereaction mixture for 3 h at room temperature, it was filtered overcelite bed and washed with ethyl acetate. The organic layer wasseparated from the filtrate and washed with water twice followed bybrine. The organic extract was dried, evaporated and purified on acolumn of silica gel.

EXAMPLES

A. General rocedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

To a solution of the starting material in dry THF at −78° C. under argonwas added 1.6M BuLi (1.2 eq) drop wise. The reaction mixture was stirredfor 45 min at the same temperature and then R-glycidyl butyrate (1.2 eq)was added. Stirred for 1 h at −78° C. Then the cold bath was removedwhile monitoring with TLC. After 3–12 h, the reaction mixture wasquenched with saturated NH₄Cl solution and extracted with ethyl acetate.The combined organic extracts were washed with water, brine and dried.The residue obtained upon evaporation of solvents was chromatographedover silica gel to afford the product.

Examples 1–19 have been prepared according to the general procedure A.

Example No. Structure Analytical Data 1

¹HNMR (DMSO-d⁶,200MHz): δ 7.68–7.50(m,2H), 7.38(d, J=8.8Hz, 1H),5.23(t,J=5.8Hz, 1H), 4.73–4.72(m, 1H), 4.47(t, J=7.4Hz, 2H), 4.14–3.80(m,4H),3.68–3.56(m, 2H). 2

¹HNMR (CDCl₃, 200MHz): δ7.73(d, J=11.6Hz, 1H), 7.52(t, J=8.8Hz, 1H),7.29(d, J=8.8Hz, 1H), 4.89(bs, 1H),4.76(t, J=2H), 4.17(t, J=8.8Hz, 2H),3.93–3.68(m,4H). 3

¹HNMR (CDCl₃, 200MHz): δ7.70(dd, J=12.7Hz and 2.2Hz, 1H), 7.44–7.26(m,2H),4.75–4.68(m, 2H) 4.37(t, J=7.8Hz, 2H), 4.04–3.56(m,4H), 3.48(t,J=7.8Hz, 2H). 4

¹HNMR (CDCl₃, 200MHz): δ7.62(dd, J=2.4Hz and 12.7Hz, 1H), 7.47(t,J=8.4Hz,1H), 7.24–7.20(m, 1H), 4.77–4.69(m, 1H), 4.10–3.81(m, 5H),3.77–3.68(m, 4H), 3.23(s, 3H). 5

¹HNMR (CDCl₃, 200MHz): δ7.85–7.79(m, 1H), 7.58(t, J=8.0Hz, 1H),7.46–7.42(m,1H), 7.30–7.18(m, 4H), 6.90–6.87(m, 1H), 4.90–4.75(m, 1H),4.15–4.07(m, 3H), 3.87–3.81(m, 1H). 6

¹HNMR (CDCl₃, 200MHz): δ7.76(dd, J=2.4Hz and 12.2Hz, 1H), 7.53–7.26(m,2H),7.11(s, 1H), 6.97(d, J=8.4Hz, 1H), 6.72(d, J=7.8Hz,1H), 4.81–4.65(m,1H), 4.09–3.82(m, 4H), 2.41(s, 3H),2.09(hump, 1H). 7

¹HNMR (CDCl₃, 200MHz): δ7.77(d, J=10.4Hz, 1H),7.57–7.26(m, 3H), 6.96(d,J=7.8Hz, 1H), 6.64(s, 1H),4.82–4.71(m, 1H), 4.14–4.05(m, 3H),3.84–3.78(m, 2H),2.35(s, 3H). 8

¹HNMR (CDCl₃, 200MHz): δ7.92–7.89(m, 2H), 7.44(d, J=7.8Hz, 1H),7.80–7.71(m,1H), 4.54(t, J=7.2Hz, 2H),4.08–3.89(m, 6H), 2.16(s, 1H). 9

¹HNMR (CDCl₃, 200MHz): δ7.69–7.48(m, 2H), 7.23(d, J=8.8Hz, 1H),4.81–4.72(m,1H), 4.54(t, J=7.4Hz, 2H),4.13–3.69(m, 6H). 10

¹HNMR (CDCl₃, 200MHz): δ7.29(d, J=10.8Hz, 2H),4.80–4.73(m, 1H), 4.57(t,J=15.6Hz, 2H), 4.00–3.73(m, 8H). 11

¹HNMR (CDCl₃, 200MHz): δ7.59(s, 4H), 5.24(t, J=5.4Hz, 1H), 4.67(bs, 1H),4.45(t, J=7.4Hz, 2H), 4.13–4.02(m, 3H), 3.88–3.54(m, 3H). 12

¹HNMR (CDCl₃, 200MHz): δ7.79(d, J=9.2Hz, 2H), 7.72(d, J=9.2Hz, 2H),7.59–7.03(m, 4H), 5.18(t, J=5.8Hz,1H), 4.80–4.71(m, 1H), 4.18–4.02(m,2H), 3.98–3.68(m, 2H). 13

¹HNMR (CDCl₃, 200MHz): δ2.9(s, 3H), 4.1(t, 1H), 3.9(m,6H), 4.7(m, 1H),4.8(s, 2H),6.8(t, 1H), 7.2(d, 1H). 14

¹HNMR (CDCl₃, 200MHz): δ7.4(dd, J=2Hz and 15.4Hz,1H), 7.2(d, J=8.8Hz,2H),7.0(d, J=9.4Hz, 1H), 6.85(d,J=8.4Hz, 2H), 6.5(t, J=9.2Hz, 1H),4.75(s, 3H), 4.50(s,2H), 3.95(m, 6H), 3.8(s, 3H). 15

¹HNMR (CDCl₃, 200MHz): δ7.55(dd, J=2.4Hz and 13.4Hz, 1H), 7.45(t,J=8.8Hz,1H), 7.10(dd, J=2.2Hz and13.0Hz, 1H), 4.66(m, 1H),3.81(m, 6H),3.47(t, 2H), 2.8(s, 3H). 16

¹HNMR (CDCl₃, 200MHz): δ2.8(s, 3H), 3.4(m, 3H), 4.7(m, 1H), 7.5(m, 4H).17

¹HNMR (CDCl₃, 200MHz): δ7.7–7.2(m, 9H), 4.8–4.6(m,1H), 4.5(s, 2H),4.1–3.7(m,6H). 3.4(t, J=8.8Hz, 2H) 18

¹HNMR (CDCl₃, 200MHz): δ7.5–7.7(m, 4H), 7.3–7.4(m,2H), 7.2(d, J=8.8Hz,1H),7.1(t, 4H), 4.7(m, 1H), 3.9–4.1(m, 6H), 3.9(s, 1H), 3.7(m, 1H). 19

¹HNMR (CDCl₃, 200MHz): δ7.5(m, 4H), 7.2(m, 1H), 7.0(m, 2H), 4.7(m, 2H),4.0(m,7H), 3.8(m, 1H)

B. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

To a solution of the alcohol, triethylamine (2.2 eq) in drydichloromethane, methane sulfonylchloride (1.1 eq) was added at 0° C.under argon. The reaction mixture was warmed to room temperature over 2h and then diluted with dichloromethane. The organic layer was washedwith water, brine and dried. The residue obtained upon evaporation ofthe solvent was taken up in dry DMF and then NaN₃ (1.5 eq) was added atroom temperature. The resultant mixture was heated to 80° C. for 2–5 hwhile monitoring by TLC. Allowed the reaction mixture to attain roomtemperature, water was added and extracted with ethyl acetate. Thecombined organic extracts were washed with water (3 times), brine anddried. The residue obtained upon evaporation of the solvent was passedthrough column to obtain the azide.

Examples 20–31 have been prepared according to the general procedure B.

Example No. Structure Analytical Data 20

¹HNMR (DMSO-d⁶,200MHz): δ 7.67–7.52(m,2H), 7.38(d, J=8.8Hz,1H),4.95–4.88(m, 1H), 4.47(t,J=7.2Hz, 2H), 4.16(t, J=9.4Hz, 1H),4.02–3.64(m, 5H). 21

¹HNMR (CDCl₃, 200MHz): δ7.62(dd, J=2.4Hz and 12.7Hz, 1H), 7.48(t,J=8.4Hz,1H), 7.22–7.17(m, 1H), 4.85–4.73(m, 1H), 4.16–3.52(m,8H),3.22(s, 3H). 22

¹HNMR (CDCl₃, 200MHz): δ7.75(dd. J=2.0Hz and 12.2Hz, 1H), 7.54(t,J=8.8Hz,1H), 7.40–7.26(m, 1H), 7.10(s, 1H), 6.97(d, J=7.8Hz,1H), 6.71(d,J=6.8Hz, 1H),4.87–4.79(m, 1H), 4.17–3.57(m, 4H), 2.41(s, 3H). 23

¹HNMR (CDCl₃, 200MHz): δ7.81(d, 1H), 7.54(t, 1H),7.45–7.01(m, 3H),6.67(s,1H), 4.91–4.79(m, 1H), 3.95–3.47(m, 4H), 2.38(s, 3H). 24

¹HNMR (CDCl₃, 200MHz): δ7.89(d, J=7.4Hz, 2H), 7.43(d, J=9.4Hz, 1H),4.87–4.80(m, 1H), 4.54(t, J=7.2Hz,2H), 4.12(t, J=8.8Hz, 2H),3.97–3.55(m,4H). 25

¹HNMR (CDCl₃, 200MHz): δ7.71–7.50(m, 2H), 7.17(d, J=8.8Hz, 1H),4.89–4.75(m,1H), 4.52(t, J=7.2Hz, 2H),4.47–3.55(m, 6H). 26

¹HNMR (CDCl₃, 200MHz): δ7.31(s, 2H), 4.83–4.81(m,1H), 4.57(t, J=7.8Hz,2H),4.09–3.55(m, 6H). 27

¹HNMR (DMSO-d⁶,200MHz): δ 7.64(s, 4H),4.98–4.89(m, 1H), 4.50(t,J=7.4Hz,2H), 4.25–4.07(m,4H), 3.88–3.70(m, 2H). 28

¹HNMR (CDCl₃, 200MHz): δ7.75(d, J=9.2Hz, 2H), 7.59(d, J=9.2Hz, 2H)7.48–7.03(m, 4H), 4.89–4.81(m, 1H),4.16(t, J=9.2Hz, 1H), 3.98–3.58(m,3H). 29

¹HNMR (CDCl₃, 200MHz): δ7.5–7.4(dd, 1H), 7.1(dd, 1H),6.5(t, 1H), 4.9(s,2H), 4.8–4.7(m, 1H), 4.1–3.5(m, 6H), 3.0(s, 3H). 30

¹HNMR (CDCl₃, 200MHz): δ7.6(m, 4H), 7.35(t, 2H), 7.0–7.2(m, 2H), 4.8(m,1H), 4.1(m, 1H), 4.0(s, 4H), 3.9(m,1H), 3.7(m, 2H). 31

¹HNMR (CDCl₃, 200MHz): δ7.6(m, 4H), 7.2(m, 1H), 7.0(m, 2H), 4.8(m, 1H),4.1(m,1H), 4.0(s, 4H), 3.9(m, 1H),3.6(m, 2H).

C. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

Procedure (i):

A solution of the azide in THF:MeOH (1:3) was hydrogenated over 10% Pdon charcoal overnight. he reaction mixture was filtered and the filtratewas concentrated. he residue was crystallized in MeOH to afford theamine.

Procedure (ii):

Triphenyl phosphine (1.3 eq) was added portion wise to a solution of theazide in dry THF and the resultant mixture was stirred at roomtemperature for 6 h. Water (few drops) was added and the reactionmixture was heated to 60° C. overnight. The solvent was evaporated andthe residue was passed through a column of silica gel to afford theamine.

Examples 32–37 have been prepared according to the general procedure C.

Example No. Structure Analytical Data 32

¹HNMR (DMSO-D⁶,200MHz): δ 7.66–7.50(m,2H), 7.37(D, j=9.4Hz,1H),4.66–4.60(m, 1H),4.47(t, J=7.8Hz, 2H),4.12–3.83(m, 6H), 2.91–2.80(m,2H).Mp: 147° C. 33

¹HNMR (CDCl₃, 200MHz):δ 7.63–7.55(dd, J=2.0Hzand 13.0Hz, 1H),7.49–7.22(m, 2H), 4.63–4.60(m, 1H)4.09(t, J=8.8Hz, 1H),4.03–3.73(m, 4H),3.32(m,3H), 3.08(s, 3H). 34

¹HNMR (CDCl₃, 200MHz):δ 8.02(s, 2H), 7.87–7.83(m,2H), 7.64(s, 1H),7.50(d, J=8.2Hz, 1H), 4.84(s, 1H),4.54(t, J=7.4Hz, 2H),4.20–3.90(m, 6H).35

¹HNMR (DMSO-d⁶,200MHz): δ 7.57(s, 4H),4.63–4.61(m, 1H), 4.44(t,J=7.2Hz,2H), 4.08–3.82(m,4H), 2.86–2.82(m, 2H). 36

¹HNMR (CDCl₃, 200MHz):δ 7.6–7.4(dd, 1H), 7.1(dd,1H), 6.6(t, 1H), 4.9(s,2H),4.6(m, 1H), 4.1–3.7(m,4H), 3.2–2.8(m, 4H). 37

¹HNMR (CDCl₃, 200MHz):δ 7.62–7.40(m, 3H), 7.3(s,5H), 4.7(m, 1H),4.5(s,2H), 4.1(t, 1H), 3.9–3.8(m,4H), 3.4(t, 2H).

D. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

A solution of amine in methyl formate was heated to 80° C. overnight.The volatiles were removed under low pressure and the residue obtainedwas passed through column to yield formate in very pure form.

Examples 38 & 39 have been prepared according to the general procedureD.

Example No. Structure Analytical Data 38

¹HNMR (CDCl₃, 200MHz):δ 8.28(s, 1H), 7.66–7.49(m,2H), 7.15(d,J=8.8Hz,1H), 6.15(bs, 1H), 4.82(m,1H), 4.52(t, J=7.4Hz, 2H),4.48–4.02(m,3H). 39

¹HNMR (CDCl₃,200MHz): δ 8.27(s, 1H),7.26–7.23(m, 2H), 6.32(bs,1H),4.82(bs, 1H), 4.58(t, J=7.2Hz, 2H), 4.214–3.68(m, 6H).

E. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring and R^(4a) represents(C₁–C₆)alkyl, (C₁–C₆)alkoxy, (C₂–C₆)alkenyl, halo(C₁–C₆)alkyl, aryloxy,(C₂–C₆)alkenyloxy, aryloxycarbonyl or (C₁–C₆)alkoxycarbonyl.

To a solution of the amine (1 eq) in dry dichloromethane at 0° C. underargon was added Et₃N (2.5 eq) followed by respective acid chloride (1.2eq) drop wise. After being stirred at room temperature for 1 to 6 h (TLCcontrol), the reaction mixture was diluted with dichloromethane andwashed with water twice followed by brine. The organic extract wasdried, evaporated and was passed through column to afford the acylatedproduct.

Examples 40–70 have been prepared according to the general procedure E.

Example No. Structure Analytical Data 40

¹HNMR (CDCl₃, 200MHz): δ7.62(dd, J=2.60Hz and 13.4Hz, 1H), 7.52(d,J=8.60Hz,1H), 7.13–7.17(m, 1H), 5.96–5.99(m, 1H), 4.82–4.76(m,1H),4.52(t, J=7.40Hz, 2H),4.01–4.09(m, 3H), 3.62–3.81(m, 3H), 2.02(s, 3H).41

¹HNMR (CDCl₃, 200MHz): δ7.66–7.49(m, 2H), 7.16(d, J=8.8Hz, 1H), 6.03(bs,1H),4.82–4.78(m, 1H), 4.52(t, J=7.8Hz, 2H), 4.09–4.0(m, 3H),3.83–3.65(m,3H), 2.24(q, J=7.8Hz, 2H), 1.13(t, J=7.8Hz, 3H).Mp: 203° C. 42

¹HNMR (CDCl₃, 200MHz): δ7.66–7.49(m, 2H), 7.15(d, J=8.8Hz, 1H), 6.01(bs,1H),4.81–4.75(m, 1H), 4.52(t, J=7.8Hz, 2H), 4.09–4.01(m,3H),3.83–3.65(m, 3H), 2.19(t, J=7.4Hz, 2H), 1.65–1.58(m, 2H), 0.98(t,J=7.4Hz, 3H).Mp: 211° C. 43

¹HNMR (CDCl₃, 200MHz): δ7.66–7.49(m, 2H), 7.15(d, J=8.8Hz, 1H),4.82–4.76(m,1H), 4.52(t, J=7.8Hz, 2H),4.09–4.01(m, 2H), 3.83–=3.65(m,3H), 2.21(t, J=7.4Hz,2H), 1.57–1.49(m, 2H), 1.38–1.20(m, 2H), 0.89(t,3H).Mp: 187° C. 44

¹HNMR (CDCl₃, 200MHz): δ7.68–7.52(m, 2H), 7.17(d,8.6Hz, 1H), 5.96(hump,1H),4.81(hump, 1H), 4.54(t, J=7.2Hz, 2H), 4.11–3.67(m,6H), 2.22(t,J=7.4Hz, 2H),1.60(bs, 8H), 0.87(s, 3H).Mp: 131° C. 45

¹HNMR (CDCl₃+DMSO-d⁶,200MHz): δ 7.97(bs, 1H),7.6–7.40(m, 2H), 7.10(d,J=8.8Hz, 1H), 6.35–6.15(m,2H), 5.63(dd, J=4.0Hz and8.3Hz, 1H),4.79–4.86(m,1H), 4.53(t, J=7.8Hz, 2H),4.05(t, J=6.8Hz, 2H), 3.89–3.56(m,4H).Mp: 196° C. 46

¹HNMR (CDCl₃+DMSO-d⁶,200MHz): δ 9.38(bs, 1H)7.67–7.5(m, 2H), 7.20(d,J=8.8Hz, 1H), 4.88–4.87(m,1H), 4.53(t, J=7.8Hz, 2H),4.16–4.02(m, 3H),3.89–3.70(m, 1H), 3.67–3.65(m, 2H).Mp: 194° C. 47

¹HNMR (CDCl₃, 200MHz): δ7.66–7.49(m, 2H), 7.15(d, J=8.8Hz, 1H),4.85–4.83(m,1H), 5.55–4.47(m, 2H), 4.37–4.31(m, 2H), 4.14–3.90(m,3H),3.88–3.60(m, 3H), 1.42(t, 3H).Mp: 160° C. 48

¹HNMR (CDCl₃, 200MHz): δ7.75–7.05(m, 3H), 6.05(bs,1H), 4.95–4.62(m 2H),4.52(t, 1H), 4.30–3.32(m, 6H),2.023(s, 3H). 49

¹HNMR (CDCl₃, 200MHz): δ7.5(d, J=7.81Hz, 2H), 7.3(d, J=7.81Hz, 2e H),4.8(s,1H), 4.4(s, 4H), 4.1(t, 1H),3.8(t, 1H), 3.5(s, 1H), 32.3(s, 1H),2.0(s, 3H). 50

¹HNMR (CDCl₃, 200MHz): δ7.99(hump, 1H), 7./73(d, J=13.0Hz, 1H), 7.43(d,J=8.0Hz, 1H) 7.31(d, J=8.8Hz,1H), 4.83(hump, 1H), 4.42(t,J=7.6Hz, 2H),4.15–3.89(m,3H), 3.62–3.55(m, 4H), 2.0(s, 3H).Mp: 220° C. 51

¹HNMR (CDCl₃, 200MHz): δ7.61(dd, J=2.6Hz and 12.7Hz, 1H), 7.48(t,J=8.4Hz,1H), 7.19(dd, J=2.6Hz and8.8Hz, 1H), 6.15(t, J=8.4Hz, 1H),4.79–4.77(m, 1H),4.05(t, J=8.8Hz, 1H), 3.97–3.88(m, 2H),3.81–3.74(m,3H), 3.69–3.61(m, 2H), 3.23(s, 3H), 2.03(s, 3H).Mp: 171° C.52

¹HNMR (CDCl₃, 200MHz): δ7.76(dd, J=2.2Hz and 12.0Hz, 1H), 7.53(t,J=8.4Hz,1H), 7.37–7.14(m, 4H), 6.82(t, J=3.4Hz, 1H), 6.03(t, J=5.4Hz,1H), 4.83–4.80(m,1H), 4.10(t, J=9.0Hz, 1H),3.88–3.80(m, 1H),3.71–3.66(m, 2H), 2.04(s, 3H). 53

¹HNMR (CDCl₃, 200MHz): δ7.74(dd, J=2.6Hz and12.2Hz, 1H), 7.53(t,J=8.4Hz, 1H), 7.49–7.26(m, 2H),7.10–6.95(m, 2H), 6.72–6.68(m, 1H),6.09–6.01(m, 1H),4.84(bs, 1H), 4.10(t, J=8.8Hz, 1H), 3.88–3.66(m,3H),2.41(s, 3H), 2.04(s, 3H).Mp: 213° C. 54

¹HNMR (CDCl₃, 200MHz): δ7.80–6.94(m, 4H), 6.63(s,1H), 6.0(bs, 1H),4.82–4.90(m, 1H), 4.11(t, J=9.2Hz,1H), 3.89–3.66(m, 3H), 2.35(s, 3H),2.09(s, 3H).Mp: 202° C. 55

¹HNMR (CDCl₃, 200MHz): δ7.93(s, 1H), 7.76(d, J=8.8Hz, 1H), 7.42(d,J=8.8Hz,1H), 6.57(bs, 1H), 4.79(bs,1H), 4.52(t, J=7.8Hz,2H),4.11–3.60(m, 6H), 1.99(s, 3H).Mp: 143° C. 56

¹HNMR (CDCl₃, 200MHz): δ7.93–7.79(m, 2H), 7.43(d, J=8.8Hz, 1H), 6.12(bs,1H),4.82–4.78(m, 1H), 4.53(t, J=7.4Hz, 2H), 4.09(t, J=9.4Hz, 1H),3.96–3.66(m, 5H),2.30–2.17(m, 2H), 1.20(t, J=9.4Hz, 3H).Mp: 143° C. 57

¹HNMR (CDCl₃, 200MHz): δ7.91(s, 1H), 7.78(d, J=8.2Hz, 1H), 6.26(bs, 1H),4.80(bs, 1H), 4.52(t, J=7.2Hz,2H), 4.06(t, J=9.4Hz, 1H),3.95–3.67(m,5H), 2.47–2.05(m, 4H), 1.83–1.54(m, 6H),0.83–0.78(m, 3H).Mp: hygroscopic58

¹HNMR (CDCl₃, 200MHz): δ7.92(s, 1H), 7.85(d, J=8.2Hz, 1H), 7.45(d,J=8.8Hz,1H), 6.40–6.07(m, 3H), 5.75(d, J=10.4Hz, 1H), 4.89(hump, 1H),4.56(t, J=7.8Hz, 2H), 4.13(t, J=9.2Hz,1H), 3.98–3.78(m, 5H).Mp: 191° C.59

¹HNMR (CDCl₃, 200MHz): δ7.65–7.41(m, 2H), 7.23(d, J=7.2Hz, 1H), 6.12(bs,1H),4.80(bs, 1H), 4.52(t, J=7.8Hz, 2H), 4.47–4.00(m, 3H),3.81–3.59(m,3H), 2.05(s, 3H).Mp: 120° C. 60

¹HNMR (CDCl₃, 200MHz): δ7.27(d, J=9.8Hz, 2H), 6.01(hump, 1H), 4.80(hump,1H),4.57(t, J=7.8Hz, 2H), 4.06–3.67(m, 6H), 2.03(s, 3H).Mp: 219° C. 61

¹HNMR (CDCl₃+DMSO-d⁶,200MHz): δ 7.32–7.26(m,2H), 7.09(hump, 1H),4.81(hump, 1H), 4.58(t, J=7.4Hz, 2H), 4.05–3.62(m, 6H),2.25–2.18(m, 2H),1.11(t, J−7.8Hz, 3H).Mp: 224° C. 62

¹HNMR (CDCl₃+DMSO-d6,200MHz): δ 7.64(s, 2H), 7.55(s, 2H), 7.09–7.25(m,1H),4.70–4.85(m, 1H), 4.46(t,2H), 4.13–3.81(m, 4H), 3.57(bs, 2H),1.96(s, 3H).Mp: 231° C. 63

¹HNMR (CDCl₃, 200MHz): δ7.70(d, J=8.8Hz, 2H), 7.54(d, J=8.8Hz, 2H),7.24–6.99(m, 4H), 6.19(bs, 1H), 4.80(m, 1H), 4.09(t, J=8.8Hz,1H),3.85(t, J=7.0Hz, 1H),3.69–3.63(m, 2H), 2.02(s, 3H).Mp: 229° C. 64

¹HNMR (CDCl₃, 200MHz): δ7.10(d, 1H), 6.6(t, 1H), 6.0(m, 1H), 4.90(s,2H), 4.9(m,1H), 4.0(s, 3H), 3.80(m, 3H),3.0(s, 3H), 2.0(s, 3H).Mp: 230°C. 65

¹HNMR (CDCl₃, 200MHz): δ7.26–7.46(m, 6H), 7.01(d,1H), 6.63(t, 1H),6.05(s, 1H),4.71–4.89(m, 2H), 4.77(s,1H), 4.60(s, 2H), 3.94–4.04(m, 3H),3.61–3.76(m, 3H),2.01(s, 3H). 66

¹HNMR (CDCl₃, 200MHz): δ7.50(m, 2H), 7.10(d, J=8.4Hz, 1H), 6.18(t, 1H),4.7(m,1H), 4.0(t, J=9.4Hz, 1H),3.6(m, 7H), 2.9(s, 3H), 2.0(s, 3H).Mp:182° C. 67

¹HNMR (CDCl₃, 200MHz): δ2.0(s, 3H), 2.8(s, 3H), 4.0(t,1H), 3.4–3.8(m,5H), 4.8(m,1H), 6.2(m, 1H), 7.6(m, 4H).Mp: 217° C. 68

¹HNMR (CDCl₃, 200MHz): δ7.6–7.3(m, 9H), 6.2(bt, 1H),4.8–4.7(m, 1H),4.5(s, 2H),4.06(t, J=9.3Hz, 1H), 3.90–3.3(m, 6H), 2.0(s, 3H).Mp: 204° C.69

¹HNMR (CDCl₃, 200MHz): δ7.70–7.50(m, 4H), 7.40–7.30(t, 2H), 7.2(d,J=8.8Hz,1H), 7.1(t, 1H), 4.80(m, 5H),4.0(m, 5H), 3.8(m, 1H), 3.6(m, 2H),2.0(s, 3H).Mp: 182° C. 70

¹HNMR (CDCl₃, 200MHz): δ8.3(m, 1H), 7.6(m, 4H), 7.3(m, 1H), 7.2(t, 2H),4.7(m,1H), 4.1(t, 1H), 3.8–4.0(m,4H), 3.7(t, 1H), 3.0(m, 2H),1.8(s,3H).Mp: 194° C.

F. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring and R^(4b) represents(C₁–C₆)alkyl, halo(C₁–C₆)alkyl, —C(═O)—(C₁–C₆)alkoxy, —C(═O)-aryloxy,—C(═S)—(C₁–C₆)alkyl or —C(═S)-aryl.

A solution of the amide (1 eq) and Lawesson's reagent (0.6 eq) in drydioxane was heated to 55 to 90° C. over 3 to 10 h (TLC control). Thereaction mixture was allowed to cool to room temperature and dilutedwith ethyl acetate. The resultant mixture was washed with water (4times) followed by brine and dried. The residue obtained uponevaporation of solvent was passed through column of silica gel to affordthe respective thioacetate.

Examples 71–80 have been prepared according to the general procedure F

Example No. Structure Analytical Data 71

¹HNMR (CDCl₃,200MHz): δ 7.94(bs, 1H),7.66–7.52(m, 2H), 7.16(d,J=7.8Hz,1H), 5.20–4.85(m, 1H), 4.54(t, J=7.8Hz, 2H), 4.25–3.82(m,6H), 2.61(s,3H).Mp: 171° C. 72

¹HNMR (CDCl₃+DMSO-d6, 200MHz): δ 10.51(s,1H), 7.64–7.47(m, 2H),7.16(d,J=8.8Hz, 1H),5.01(bs, 1H), 4.53(t, J=7.2Hz, 2H), 4.29–3.89(m,4H),3.63(q, J=10.2Hz, 2H).Mp: 165° C. 73

¹HNMR (CDCl₃,200MHz): δ 7.90(bs, 1H),7.61(dd, J=2.4Hz and12.8Hz, 1H),7.50(t, J=8.2Hz, 1H), 7.19(dd, J=2.4Hz and 12.8Hz, 1H),5.0(m, 1H),4.25–3.74(m,8H), 3.24(s, 3H), 2.6(s, 3H).Mp: 111° C. 74

¹HNMR (CDCl₃,200MHz): δ 7.87–7.74(m,2H), 7.57(t, J=8.2Hz,1H),7.39–7.18(m, 4H),6.87–6.85(m, 1H), 5.08–5.05(m, 1H), 4.37–4.27(m, 1H),4.23–4.06(m,2H), 3.94(t, J=6.8Hz,1H), 2.62(s, 3H).Mp: 137° C. 75

¹HNMR (CDCl₃,200MHz): δ 8.1(s, 1H),7.9(s, 1H), 7.8(d, J=8.7Hz, 1H),7.4(d, J=8.79,1H), 5.0(s, 1H), 4.6(t,2H), 4.0(m, 6H), 2.6(s, 3H).Mp:154° C. 76

¹HNMR (CDCl₃+DMSO-d⁶, 200MHz): δ 10.37(bs,1H), 7.50(d, J=10.8Hz,2H),4.98(bs, 1H), 4.55(t,J=7.8Hz, 2H), 4.23–3.78(m, 6H), 2.50(s, 3H).Mp:108° C. 77

¹HNMR (CDCl₃,200MHz): δ 7.86(bt, 1H),7.28(d, J=9.6Hz, 2H),5.02–4.99(m,1H), 4.58(t,J=7.4Hz, 2H), 4.24–3.80(m, 6H), 2.71(q, J=7.4Hz,2H), 1.29(t,J=7.8Hz, 3H).Mp: 168° C. 78

¹HNMR (CDCl₃,200MHz): δ 7.86(hump,1H), 7.25(d, J=9.6Hz,2H), 5.02–4.99(m,1H),4.58(t, J=7.4Hz, 2H),4.24–3.80(m, 6H), 2.71(q,J=7.4Hz, 2H), 1.29(t,J=7.8Hz, 3H).Mp: 195° C. 79

¹HNMR (CDCl₃,200MHz): δ 8.4(1H), 7.5(m, 2H), 7.0(d, J=8.8Hz,2H), 4.9(m,1H), 3.9(m,6H), 3.5(t, J=8.8Hz,2H), 2.9(s, 3H), 2.5(s, 3H).Mp: 168° C.80

¹HNMR (CDCl₃,200MHz): δ 7.6(m, 4H),7.4(m, 2H), 7.2(d, J=8.8Hz, 1H),7.0(t, 1H), 5.0(m, 1H), 4.0(m, 8H), 2.6(s, 3H).Mp: 165° C.

G. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

To a solution of the amine (1 eq), Et₃N (2.2 eq) in dry dichloromethanemethyl chloroformate under argon was added at 0° C. (1.2 eq). Thereaction mixture was stirred at room temperature overnight and worked upby diluting with dichloromethane followed by washing with water andbrine. The residue obtained after evaporation of the dried organic layerwas passed through column to afford the carbamate.

Examples 81–85 have been prepared according to the general procedure G

Example No. Structure Analytical Data 81

¹HNMR (CDCl₃, 200MHz):δ 7.68–7.49(m, 2H), 7.16(d,J=8.4Hz, 1H),5.16(bs,1H), 4.78(bs, 1H), 4.52(t, J=7.2Hz, 2H), 4.09–4.0(m,3H),3.84–3.55(m, 6H).Mp: 153° C. 82

¹HNMR (CDCl₃, 200MHz):δ 7.9(m, 2H), 7.4(d, J=8.3Hz, 1H), 5.2(s, 1H),4.8(s,1H), 4.5(t, 1H), 4.0(m, 9H).Mp: 148° C. 83

¹HNMR (CDCl₃, 200MHz):δ 7.27(d, J=6.8Hz, 2H),5.16(bs, 1H),4.84–4.80(m,1H), 4.58(t, J=7.2Hz, 2H),4.07–3.60(m, 9H).Mp: 157° C. 84

¹HNMR (CDCl₃+DMSO-d⁶,200MHz): δ 7.57(s, 4H),6.98(bs, 1H),4.96–4.76(m,1H), 4.51(t, J=7.4Hz, 2H),4.47(m, 3H), 3.91–3.84(m,1H),3.65(s, 1H), 3.51(bs, 3H).Mp: 195° C. 85

¹HNMR (CDCl₃, 200MHz):δ 3.0(s, 3H), 3.8(m, 6H),4.8(m, 1H), 4.9(s, 2H),5.1(m, 1H), 6.6(t, 1H).Mp: 226° C.

H. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring and R^(4c) represents(C₁–C₆)alkyl group.

To an ice cold mixture of amine (1 eq), Et₃N (2 eq) and water (fewdrops) in EtOH CS₂ (1 eq) was added under argon. Stirred overnight atroom temperature, Methyl iodide (MeI) (1.1 eq) in EtOH was added and thestirring was continued for 12 h. The volatiles were removed and theresidue was taken up in ethyl acetate. The organic mixture was washedwith saturated NaHCO₃, water, brine and dried. The residue obtained waspassed through column to afford the product.

Examples 86 and 87 have been prepared according to the general procedureH.

Example No. Structure Analytical Data 86

¹HNMR (CDCl₃+DMSO-d6,200MHz): δ 9.98(bt, 1H),7.55(s, 4H),5.05–5.02(m,1H), 4.50(t, J=7.8Hz, 2H),4.12–3.87(m, 6H), 2.60(s, 3H).Mp:161° C. 87

¹HNMR (DMSO-d6,200MHz): δ 7.26(s, 1H), 6.15(d, J=10.2Hz, 2H),4.56–4.49(m, 3H), 4.27–3.83(m,5H), 3.26–3.15(m, 1H), 2.54(s, 3H).Mp:147° C.

I. General procedure for the conversion of

Step (i):

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring.

Thiophosgene (1.2 eq) was added drop wise to a solution of the amine (1eq), Et₃N (2.4 eq) in dry dichloromethane at ice bath temperature underargon. The reaction mixture was warmed to room temperature over 3 h andthen the volatiles were removed. The residue obtained was directlycharged on to a column of silica gel to afford the product.

Step (ii):

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring and R^(4d) represents(C₁–C₆)alkyl, cyclo(C₃–C₆)alkyl, —(C═O)—(C₁–C₆)alkyl group substitutedwith fluorine; aryl, halo(C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl,(C₁–C₆)alkoxy(C₁–C₆)alkyl or (C₂–C₆)alkenyl.

A solution of the isothiocyanate in the respective alcohol was heated to80 to 100° C. while monitoring by TLC. At the complete consumption ofstarting material, the reaction mixture was allowed to cool to roomtemperature. The crystals formed were separated, washed with ether anddried at vacuum to yield the pure product.

Examples 88–124 have been prepared according to the general procedure I

Example No. Structure Analytical Data 88

¹HNMR (CDCl₃, 200MHz): δ7.67–7.56(m, 2H), 7.16(d, J=2.0Hz, 1H), 6.72(bs,1H),4.94(bs, 1H), 4.52(t, J=7.8Hz, 2H), 4.12–3.83(m, 9H).Mp: 137° C. 89

¹HNMR (CDCl₃, 200MHz): δ7.66–7.50(m, 2H), 7.15(d, J=7.4Hz, 1H),6.66(hump, 1H),4.94(bs, 1H), 4.56–4.43(m,4H), 4.12–3.84(m, 6H), 1.32(t,J=6.8Hz, 3H).Mp: 208° C. 90

¹HNMR (CDCl₃+DMSO-d⁶,200MHz): δ 8.45(bs, 1H),7.65–7.46(m, 2H), 7.17(d,J=8.8Hz, 1H), 4.81(bs, 1H),4.53(t, J=7.4Hz, 2H), 4.09–3.99(m, 3H),3.84–3.55(m,3H), 3.13(q, J=10.4Hz, 2H).Mp: 184° C. 91

¹HNMR (DMSO-d⁶,200MHz): δ 9.54(m, 1H),7.57(s, 4H), 4.90–4.80(m,2H),4.44(t, J=7.4Hz, 2H),4.21–4.01(m, 4H), 3.88–3.77(m, 3H), 3.56–3.53(m,1H),1.23–0.97(m, 6H).Mp: 153° C. 92

¹HNMR (CDCl₃, 200MHz): δ8.2(m, 1H), 7.7(d, J=10.74Hz, 1H), 7.5(t, 1H),7.3(d, J=8.79Hz, 1H), 5.0(m, 1H),4.70(t, 2H), 4.1(m, 9H).Mp: 197° C. 93

¹HNMR (CDCl₃, 200MHz): δ7.02(dd, J=2.4Hz and 12.8Hz, 1H), 7.49(t,J=8.8Hzand 12.8Hz, 1H), 7.20(dd, J=2.4Hz and 12.8Hz, 1H),6.63(bs, 1H),4.93(m, 1H),4.54–4.44(q, J=7.4Hz, 2H),4.13–3.72(m, 8H), 3.24(s,3H),1.32(t, J=7.0Hz, 3H).Mp: 197° C. 94

¹HNMR (CDCl₃, 200MHz): δ7.62(dd, J=2.4Hz and 12.6Hz, 1H), 7.49(t,J=8.8Hz,1H), 7.20(dd, J=2.4Hz and12.6Hz, 1H), 6.65(bs, 1H),4.94(m, 1H),4.38(t, J=8.8Hz, 2H), 4.13–3.73(m, 8H),3.24(s, 3H), 1.78–1.63(m,2H),0.99(t, 3H).Mp: >200° C. 95

¹HNMR (CDCl₃, 200MHz): δ7.62(dd, J=2.4Hz and 12.7Hz, 1H), 7.49(t,J=8.8Hz,1H), 7.20(dd, J=2.4Hz and12.7Hz, 1H), 6.70(bs, 1H),4.94(m, 1H),4.13–3.72(m,11H), 3.24(s, 3H).Mp: 179° C. 96

¹HNMR (CDCl₃, 200MHz): δ7.62(dd, J=2.4Hz and 12.7Hz, 1H), 7.49(t,J=8.8Hz,1H), 7.20(dd, J=2.4Hz and13.0Hz, 1H), 6.55(bs,1H),5.58–5.49(heptet, 1H), 4.92(m, 1H), 4.13–3.73(m, 8H),3.24(s, 3H),1.39–1.25(m, 6H).Mp: 183° C. 97

¹HNMR (CDCl₃, 200MHz): δ7.9(m, 2H), 7.5(d, J=8.79Hz, 1H), 6.7(s, 1H),5.0(s,1H), 4.5(t, 2H), 4.0(m, 9H).Mp: 146° C. 98

¹HNMR (CDCl₃, 200MHz): δ7.8(m, 2H), 7.4(d, J=8.79Hz, 1H), 6.7(s, 1H),5.0(s,1H), 4.5(m, 4H), 4.0(m, 6H),1.3(m, 3H).Mp: 157° C. 99

¹HNMR (CDCl₃, 200MHz): δ7.29–7.24(m, 2H), 6.73(hump, 1H),4.96(huimp,1H), 4.58(t, J=7.4Hz, 2H),4.08–3.83(m, 9H).Mp: 182° C. 100

¹HNMR (CDCl₃, 200MHz): δ7.52(s, 4H), 6.81(bs, 1H),4.91(hump, 1H),4.49(t, J=7.8Hz, 2H), 4.13–3.82(m, 9H).Mp: 153° C. 101

¹HNMR (CDCl₃, 200MHz): δ7.5(s, 4H), 6.7(s, 1H), 4.9(s,1H), 4.5(m, 4H),4.0(m, 6H),1.3(t, J=6.8Hz, 3H).Mp: 168° C. 102

¹HNMR (CDCl₃, 200MHz): δ7.54(s, 4H), 6.7(s, 1H), 4.9(m, 1H), 4.4(m, 4H),4.0(m,6H), 1.7(m, 2H), 0.95(t, J=7.4Hz, 3H).Mp: 176° C. 103

¹HNMR (CDCl₃, 200MHz): δ7.52(s, 4H), 7.26(bs, 1H),4.96–4.77(m, 3H),4.50(t,J=7.2Hz, 2H), 4.15–3.80(m, 6H).Melting Point (° C.): 181° C. 104

¹HNMR (CDCl₃, 200MHz): δ9.2–8.9(m, 1H), 7.5(s, 4H),5.0–4.8(m, 1H),4.6–4.4(m,4H), 4.2–3.5(m, 8H).Mp: 141° C. 105

¹HNMR (CDCl₃, 200MHz): δ7.54(s, 4H), 6.81(bt, 1H),4.91(m, 1H),4.67–4.58(m,2H), 4.50(t, J=7.2Hz, 2H),4.13–3.82(m, 6H), 3.68–3.63(m,2H), 3.38(s, 3H).Mp: 149° C. 106

¹HNMR (CDCl₃, 200MHz): δ7.55(s, 4H), 7.26(s, 2H), 6.7(s, 1H), 5.93(m,1H), 5.29(m,2H), 4.9(m, 3H), 4.5(t, J=7.4Hz, 2H), 4.0(m, 6H).Mp: 150° C.107

¹HNMR (CDCl₃, 200MHz): δ7.54(s, 4H), 6.57(s, 1H), 5.5(m, 1H), 4.92(m,1H), 4.5(t,J=7.4Hz, 2H), 4.0(m, 6H),1.31(dd, J=10.2Hz and 13.8Hz,6H).Mp: 140° C. 108

¹HNMR (CDCl₃, 200MHz): δ7.72(d, J=9.2Hz, 2H), 7.57(d, J=9.2Hz, 2H),7.31–7.01(m, 4H), 6.77(bs, 1H), 4.97–4.96(m, 1H), 4.19–3.91(m, 7H).Mp:141° C. 109

¹HNMR (CDCl₃, 200MHz): δ7.73(d, J=8.8Hz, 2H), 7.56(d, J=8.8Hz, 2H),7.31–7.01(m, 4H), 6.70(bs, 1H), 4.97(m, 1H), 4.55–4.44(q, J=6.8Hz, 2H),4.19–3.92(m, 4H),1.32(t, J=7.0Hz, 3H).Mp: 147° C. 110

¹HNMR (CDCl₃, 200MHz): δ2.8(s, 3H), 4.8(t, 1H), 3.6(m,8H), 6.8(t, 1H),7.2(d, 1H),7.5(dd, 1H).Mp: 218° C. 111

¹HNMR (CDCl₃, 200MHz): δ1.5(s, 3H), 2.9(s, 3H), 3.6(t,2H), 4.9(m, 1H),6.8(m, 1H),7.8(d, 2H).Mp: 209° C. 112

¹HNMR (DMSO-d⁶,200MHz): 9.5(br, 1H), 7.4(d,J=8.8Hz, 2H), 6.6(d, J=8.8Hz,2H), 4.90–4.80(m, 1H),4.7(s, 2H), 4.2–3.4(m, 9H),2.9(s, 3H).Mp: 205° C.113

¹HNMR (CDCl₃, 200MHz): δ7.5(m, 2H), 7.1(m, 1H), 6.9(s, 1H), 4.9(m, 1H),3.8(m,9H), 3.4(t, J=8.8Hz, 2H),2.9(s, 3H).Mp: 146° C. 114

¹HNMR (CDCl₃, 200MHz): δ7.6–7.2(m, 9H), 6.7(bt, 1H),5.0–4.8(m, 1H),4.5(s, 2H),4.2–3.6(m, 9H), 3.4(t, J=8.8Hz, 2H).Mp: 170° C. 115

¹HNMR (CDCl₃, 200MHz): δ7.6–7.2(m, 9H), 6.7(bt, 1H),5.0–4.8(m, 1H),4.6–4.4(m,4H), 4.2–3.6(m, 6H), 3.7(t,J=8.3Hz, 2H), 1.3(t, J=6.8Hz,3H).Mp: 160° C. 116

¹HNMR (CDCl₃, 200MHz): δ9.5(m, 1H), 7.6(m, 4H), 7.4(m, 3H), 7.0(m, 1H),4.9(m,1H), 4.2(m, 1H), 3.8–4.0(m,7H), 3.3(s, 3H).Mp: 174° C. 117

¹HNMR (CDCl₃, 200MHz): δ9.5(m, 1H), 7.6(m, 4H), 7.3(m, 3H), 7.1(t, 1H),4.8(m,(1H), 4.4(m, 2H), 4.2(m, 1H),3.7–4.1(m, 5H), 3.5(m, 2H),1.2(t,3H).Mp: 195° C. 118

¹HNMR (CDCl₃, 200MHz): δ7.5(m, 4H), 7.0(m, 4H), 4.9(m, 1H), 4.0(11H).Mp:208° C. 119

¹HNMR (CDCl₃, 200MHz): δ7.6(m, 4H), 7.0–7.2(m, 3H),4.9(m, 2H), 4.5(m,2H), 4.0(m, 8H), 1.3(t, 3H).Mp: 215° C. 120

¹HNMR (CDCl₃, 200MHz): δ7.5(m, 4H), 7.0(m, 3H), 5.5(m, 1H), 4.9(m, 1H),4.0(m,8H), 1.3(t, 6H).Mp: 220° C. 121

¹HNMR (DMSO-d⁶, 200MHz): δ 9.60–9.40(m, 1H),7.57(s, 4H),5.00–4.75(m,1H), 4.44–3.40(m, 12H), 2.16(s, 6H).Mp: 161° C. 122

¹HNMR (CDCl₃, 200 MHz): δ7.40(dd, J=17.6, 2.4Hz,1H), 7.24(d, J=9.7Hz,2H),7.04(d, J=8.8Hz, 1H), 6.89(d, J=8.8Hz, 2H), 6.78(bt,1H),6.58–6.49(m, 1H), 5.00–4.80(m, 1H), 4.75(s, 2H),4.54(s, 2H),4.20–3.60(m,9H), 3.81(s, 3H).Mp: 158° C. 123

¹HNMR (DMSO-d⁶, 200MHz): δ 9.50–9.35(m, 1H),7.60–6.60(m, 8H),5.50–5.30(m, 1H), 4.95–4.70(m, 1H),4.74(s, 2H), 4.55(s, 2H),4.20–3.25(m,6H), 1.40–1.10(bd, 6H).Mp: 192° C. 124

¹HNMR (DMSO-d⁶, 200MHz): δ 9.55–9.35(m, 1H),7.45(d, J=18.1Hz, 1H),7.15(d, J=8.8Hz, 1H), 6.90–6.80(m, 1H), 6.09(t, J=6.8Hz,1H), 4.87(s,2H), 4.90–4.75(m, 1H), 4.71(d, J=6.8Hz,2H), 4.20–3.10(m, 9H).Mp: 184° C.

J. General procedure for the conversion of

where

Ar=Substituted or unsubstituted phenyl ring.

Sodium hydride (360 mg, 7.5 mmol) was added to a solution of startingmaterial (300 mg, 0.75 mmol) in dry THF (30 mL) and the resultantsuspension was stirred at room temperature overnight. The reactionmixture was diluted with ethyl acetate (150 mL) and washed with water,brine and dried. The residue obtained upon evaporation of solvent waspassed through a column of silica gel to afford the product as acolorless solid (150 mg, 54% yield).

Example 125 has been been prepared according to the general procedure J.

Example No. Structure Analytical Data 125

¹H NMR (DMSO-d⁶, 200MHz): δ 9.60–9.40 (m, 1H),8.62 (s, 1H), 7.45 (d, J=16.2 Hz, 1H), 7.16 (d, J =8.6 Hz, 1H), 6.90–6.80 (m,1H), 4.90–4.75 (m,1H), 4.73(s, 2H), 4.20–3.40 (m, 9H).Mp: 223° C.

K. General procedure for the conversion of

where

Ar=Substituted phenyl ring and R^(b) represents (C₁–C₆)alkyl or aralkyl.

To a solution of starting material (1 eq) in dry DMF was added NaH (1.2eq) at 0° C. under argon followed by appropriate alkyl halide or aralkylhalide (1.2 eq). The reaction mixture was stirred for 2–6 h whilemonitoring by TLC. After the consumption of starting material, thereaction mixture was diluted with ethyl acetate and washed with water,brine and dried. The residue obtained upon evaporation of solvent waspassed through a column of silica gel to afford the product.

Example 126–129 have been been prepared according to the generalprocedure K.

Example No. Structure Analytical Data 126

¹H NMR (DMSO-d⁶, 200MHz): δ 9.60–9.40 (m, 1H),7.49 (dd, J = 15.6, 2.4Hz,1H), 7.18 (d, J = 9.1 Hz,1H), 6.95–6.80 (m, 1H), 5.17(s, 2H),4.95–4.70 (m, 1H),4.42 (s, 2H), 4.20–3.40 (m,7H).Mp: 195° C. 127

¹H NMR (CDCl₃, 200MHz): δ 7.46 (dd, J = 15.1,2.4 Hz, 1H), 7.10 (d, J =8.8Hz, 1H), 6.77 (bt, 1H), 6.65–6.56 (m, 1H), 4.97 (s, 2H),4.97–4.80 (m,1H), 4.84 (s,2H), 4.20–3.55 (m, 9H), 3.37(s, 3H).Mp: 160° C. 128

¹H NMR (CDCl₃ + DMSO-d⁶, 200 MHz): δ 9.95–9.25(m, 1H), 7.55–7.25 (m,6H),7.45 (d, J = 15.4 Hz, 1H),6.63–6.54 (m, 1H), 5.00–4.80(m, 1H), 4.77(s, 2H), 4.60(s, 2H), 4.20–3.75 (m, 9H).Mp: 176° C. 129

¹H NMR (CDCl₃, 200MHz): δ 7.50–7.20 (m, 6H),7.04 (d, J = 8.6 Hz,1H),6.78 (bt, 1H), 6.58–6.49 (m,1H), 5.00–4.35 (m, 7H),4.20–3.60 (m,6H), 1.31 (t, J =7.0 Hz, 3H).Mp: 184° C.

L. General procedure for the conversion of

where

Ox=2-Oxazolidinone or its equivalent derivatives. An equivalentderivative of 2-oxazolidinone is a five membered heterocyclic groupcontaining two heteroatoms selected from oxygen, nitrogen and sulfur;and substituted by an ═O or ═S group, the heterocycle may be fused withsubstituted or unsubstituted phenyl group.

Ar=Substituted or unsubstituted phenyl ring and R′ represents hydrogen,(C₁–C₆)alkyl, (C₂–C₆)alkenyl, substituted or unsubstituted aralkyl,heteroaralkyl, hydroxy(C₁–C₆)alkyl, R″ represents hydrogen or alkyl orthe two R′ and R″ groups together form a 5 or 6 membered cyclicstructures containing one or two hetero atoms.

Ammonia gas (or appropriate amine) was bubbled to a solution ofisothiocyanate in THF at −10° C. over 20 min. The resultant mixture wasstirred at room temperature for 1 h and then diluted with ethyl acetate.The organic layer was washed with water (2 times), brine and dried. Theresidue obtained upon evaporation of the solvent was passed through acolumn of silica gel to afford the product.

Examples 130–143 have been prepared according to the general procedure L

Example No. Structure Analytical Data 130

¹HNMR (CDCl₃, 200 MHz):δ 7.51 (s, 4H), 4.98–4.95 (m,1H), 4.49 (t, J =7.8 HZ, 2H),4.17–3.88 (m, 8H), 3.71–3.69(m, 3H), 1.93–1.78 (m, 4H).Mp:159° C. 131

¹HNMR (DMSO-d⁶,200 MHz): δ 7.63 (s, 1H),7.57 (s, 4H), 4.94–4.91 (m,1H),4.44 (t, J = 7.4 Hz, 2H),4.17–3.75 (m, 6H), 3.66–3.56(q, J = 6.8 Hz,4H), 1.07 (t,J = 6.8 Hz, 6H).Mp: 103° C. 132

¹HNMR (DMSO-d⁶,200 MHz): δ 7.79 (bs, 1H),7.57 (s, 4H), 5.80–5.75 (m,1H),5.15–5.01 (m, 2H), 4.86(m, 1H), 4.44 (t, J = 7.4 Hz,2H), 4.17–4.01 (m,5H), 3.85(m, 2H).Mp: 171° C. 133

¹HNMR (DMSO-d⁶,200 MHz): δ 8.05 (bs, 1H),7.86 (bs, 1H), 7.57 (s,4H),7.25 (s, 5H), 4.88–4.84 (m,1H), 4.67 (s, 2H), 4.44 (t,J = 7.8 Hz,2H), 4.16–4.01 (m,3H), 3.89–3.86 (m, 3H).Mp: 181° C. 134

¹HNMR (DMSO-d⁶,200 MHz): δ 8.00 (bs, 1H),7.80 (bs, 1H), 7.57 (s,4H),7.19–7.15 (d, J = 8.4 Hz, 2H),6.84–6.80 (d, J = 8.2 Hz, 2H),4.86(bs, 1H), 4.57 (bs, 2H),4.44 (t, J = 7.4 Hz, 2H), 4.08–4.01 (m, 3H),3.88–3.85 (m,3H), 3.70 (s, 3H).Mp: 169° C. 135

¹HNMR (DMSO-d⁶,200 MHz): δ 8.50–8.48 (d,J = 3.8 Hz, 1H), 8.16 (m,2H),7.69 (t, J = 7.8 Hz, 1H), 7.57(s, 4H), 7.26–7.22 (d, J = 7.8Hz, 2H),4.88 (m, 1H), 4.75(bs, 2H), 4.44 (t, J = 7.2 Hz,2H), 4.18–4.01 (m,3H),3.89–3.82 (m, 3H).Mp: 165° C. 136

¹HNMR (DMSO-d⁶,200 MHz): δ 7.77 (bs, 1H),7.57 (s, 5H), 4.86 (m, 1H),4.44(t, J = 7.8 Hz, 2H), 4.17–4.01 (m, 3H), 3.81–3.33 (m,3H), 2.83 (bs,3H).Mp: 175° C. 137

¹HNMR (DMSO-d⁶,200 MHz): δ 7.86 (hump,1H), 7.66 (hump, 1H), 7.57(s, 4H),4.78–4.68 (m, 2H),4.43 (t, J = 7.2 Hz, 2H), 4.12–4.01 (m, 3H), 3.83 (bs,3H),3.46–3.33 (m, 4H).Mp: 161° C. 138

¹HNMR (DMSO-d⁶,200 MHz): δ 8.05 (hump,1H), 7.57 (s, 4H), 4.95 (m,1H),4.43 (t, J = 7.2 Hz, 2H),4.08–3.89 (m, 8H), 2.57 (s,4H), 2.49 (s,4H).Mp: 159° C. 139

¹HNMR (DMSO-d⁶,200 MHz): δ 12.06 (bs, 1H),10.76 (s, 1H), 8.14–8.11 (d,J= 5.0 Hz, 1H), 7.77 (t, J = 8.2Hz, 1H), 7.52 (s, 4H), 7.17–7.13 (d, J =3.2 Hz, 1H), 7.04(t, J = 5.8 Hz, 1H), 5.05–5.03(m, 1H), 4.43 (t, J = 7.4Hz, 2H), 4.22 (t, J = 9.2 Hz, 1H),4.07–3.84 (m, 5H).Mp: 189° C. 140

¹HNMR (CDCl₃ + DMSO-d⁶,200 MHz): δ 8.07 (bs, 1H),7.62–7.40 (m, 2H), 7.16(d, J =7.8 Hz, 1H), 6.65 (bs, 1H),4.85 (bs, 1H), 4.48 (t, J = 8.0Hz,2H), 4.04–3.96 (m, 6H).Mp: 178° C. 141

¹HNMR (CDCl₃ +DMSO-d⁶,200 MHz): δ 7.68–7.19 (m,5H), 4.92 (hump, 1H),4.53(t, J = 7.8 Hz, 2H), 4.08–3.98(m, 6H), 3.10 (s, 3H).Mp: 144° C. 142

¹HNMR (CDCl + DMSO-d⁶,200 MHz): δ 8.10 (bs, 1H),7.35 (d, J = 8.4 Hz,2H),6.58 (bs, 1H), 4.91–4.89 (m,1H), 4.58 (t, J = 7.8 Hz, 2H),4.54–3.87(m, 6H).Mp: 92° C. 143

¹HNMR (CDCl₃, 200 MHz):δ 7.26 (s, 2H), 6.39 (hump,2H), 4.93 (hump, 1H),4.60(t, J = 7.4 Hz, 2H), 4.21–3.93(m, 6H), 2.99 (d, J = 4.8 Hz,3H).Mp:113° C.N1-((5S)-3-{4-[2-oxo-1,3-oxazolan-3yl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-(N,N-dimethylamino)ethylthiocarbamatehydrochloride

-   -   N1-((5S)-3-{4-2-oxo-1,3-oxazolan-3yl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-(N,N-dimethylamino)ethylthiocarbamate        (obtained in Example 121), was taken in methanol (100 mg) and        was bubbled with HCl gas for 30 min. Then methanol was        evaporated from the resultant mixture and washed with ether        twice to obtain the title compound (Yield: 100%). Mp: 100° C.        (hygroscopic).

¹H NMR (DMSO-d⁶, 200 MHz): δ 10.60 (bs, 1H), 9.85–9.65 (m, 1H), 7.58 (s,4H), 5.00–4.65 (m, 3H), 4.44 (t, J=7.6 Hz, 2H), 4.25–3.40 (m, 8H), 2.81(s, 3H), 2.79 (s, 3H).

In vitro Data

Minimum Inhibiton Concentrations (MICs) were determined by brothmicrodilution technique as per the guidelines prescribed om the fifthedition of Approved Standards, NCCLS document M7-A5 Vol 20—No 2, 2000Villinova, Pa.

Initial stock solution of the test compound was prepared in DMSO.Subsequent two fold dilutions were carried out in sterile Mueller HintonBroth (Difco) (MHB).

Frozen cultures stocks were inoculated into 50 ml sterile MHB in 250 mlErlyn Meyer flasks.

Composition of MHB is as follows:

-   -   Beef Extract Powder—2.0 g/liter    -   Acid Digest of Casein—17.5 g/liter    -   Soluble Starch—1.5 g/liter

Final pH 7.3±0.1

Flasks were incubated for 4 to 5 h at 35° C. on a rotary shaker at 150rpm. Inoculum was prepared by diluting the culture in sterile MHB toobtain a turbidity of 0.5 McFarland standard. This corresponds to1–2×10⁸ CFU/ml. The stock was further diluted in sterile broth to obtain1–2×10⁶ CFU/ml. 50 μl of the above diluted inoculum was added from 1–10wells. The plates were incubated overnight at 37° C.

MIC is read as the lowest concentration of the compound that completelyinhibits growth of the organism in the microdilution wells as detectedby the unaided eye.

DRCC Organism Culture No. No. Staphylococcus aureus ATCC 33591 019Staphylococcus aureus ATCC 49951 213 Staphylococcus aureus ATCC 29213035 Enterococcus faecalis ATCC 29212 034 Enterococcus faecalis NCTC12201 153 Enterococcus faecium NCTC 12202 154 Escherichia coli ATCC25922 018

-   -   ATCC: American Type Culture Collection, USA    -   NCTC: National Collections of Type Cultures, Colindale, UK    -   DRCC: Dr. Reddy's Culture Collection, Hyderabad, India.        -   The in vitro antibacterial activity data is shown in TABLE            1.

TABLE 1 In vitro Activity of Compounds against Gram positive and Gramnegative bacteria Antimicrobial Screening (MIC) μg/ml Staphylococcusaureus Enterococcus sp E coli Example 019 213 035 034 153 154 18 No.MRSA Smith S S S R R S 40 8.0 4.0 8.0 16.0 8.0 8.0 32.0 62 2.0 1.0 4.0 —8.0 8.0 32.0 76 2.0 2.0 4.0 4.0 4.0 4.0 >32.0 79 2.0 2.0 4.0 4.0 8.0 8.032.0 88 1.0 1.0 2.0 2.0 2.0 2.0 >32.0 89 4.0 4.0 4.0 8.0 8.0 8.0 >32.099 2.0 2.0 2.0 2.0 2.0 2.0 >32.0 100 0.5 0.5 0.5 1.0 1.0 1.0 32.0 1072.0 4.0 4.0 8.0 4.0 4.0 32.0 110 0.5 0.5 0.5 1.0 1.0 1.0 32.0 113 2.04.0 4.0 4.0 4.0 8.0 32.0 124 0.25 0.25 0.5 0.5 0.25 0.5 — 125 0.25 0.250.5 0.5 0.25 0.5 — 127 0.5 1.0 1.0 1.0 1.0 1.0 —

1. A compound of the formula (I)

wherein R¹ represents halo, azido, isothiocyanate, thioalcohol, OR⁴,NHR⁴ or N(R⁴)₂, where R⁴ represents substituted or unsubstituted groupsselected from acyl, thioacyl, (C₁–C₆)alkoxycarbonyl, (C₃–C₆)ycloalkoxythiocarbonyl, (C₂–C₆) alkenyloxycarbonyl, (C₂–C₆)alkenylcarbonyl, aryloxycarbonyl, (C₁–C₆)alkoxythiocarbonyl,(C₂–C₆)alkenyloxythio-carbonyl, aryloxythiocarbonyl, —C(═O)—C(═O)-alkyl,—C(═O)—C(═O)-aryl, —C(═O)—C(═O)-alkoxy, —C(═O)—C(═O)-aryloxy,—(C═S)—S-alkyl, —(C═S)—NH₂, —(C═S)—NH-alkyl, —C(═S)—N-(alkyl)₂,—C(═S)—NH-alkenyl, (C═S)—(C═O)-alkoxy, —(C═S)—(C═O)-aryloxy,—C(═S)—O—(C═O)-alkyl, C(═S)—C(═S)-alkyl, —C(═S)—C(S)-aryl,thiomorpholinylthiocarbonyl or pyrrolidinylthiocarbonyl; R² and R³ aresame or different and independently represent hydrogen, halogen atom,(C₁–C₆)alkyl group, halo(C₁–C₆)alkyl, cyano, nitro, SR^(a), NR^(a),OR^(a) where R^(a) represents substituted or unsubstituted (C₁–C₆)alkylgroup, or halo(C₁–C₆)alkyl; Z represents O, Y¹ represents ═O or ═S groupand Y² and Y³ independently represent hydrogen, halogen, cyano, nitro,formyl, hydroxy, amino, ═O, ═S group, or substituted or unsubstitutedgroups selected from (C₁–C₆)alkyl, hydroxy(C₁–C₆)alkyl, (C₁–C₆)alkoxy(C₁–C₆) alkyl, (C₁–C₆)alkoxycarbonyl, carboxy(C₁–C₆)alkyl,(C₁–C₆)alkylsulfonyl, (C₁–C₆)alkylcarbonyl-amino(C₁–C₆) lkyl,arylcarbonylamino(C₁–C₆)alkyl, (C₁–C₆) alkylcarbonyloxy(C₁–C₆)alkyl,amino (C₁–C₆)alkyl, mono(C₁–C₆)alkylamino, di(C₁–C₆)alkylamino,arylamino, (C₁–C₆)alkoxy, aryl, aryloxy, aralkyl, heteroaryl,heteroaralkyl, heterocyclyl or heterocycloalkyl; Y² and Y³ when presenton adjacent carbon atoms together also form a substituted orunsubstituted 5 or 6 membered aromatic or non-aromatic cyclic structure,optionally containing one or two hetero atoms; its stereoisomers, itspolymorphs, its pharmaceutically acceptable salts or itspharmaceutically acceptable solvates.
 2. The compound according to claim1, wherein the substituents on R⁴ are selected from halogen, hydroxy,amino, monoalkylamino, dialkylamino, cyano, nitro, alkoxy, aryl,hydroxyaryl, pyridyl, hydroxyalkyl, alkoxyaryl or carboxyl and itsderivatives.
 3. The compound according to claim 1, wherein thesubstituents on Y² and Y³ are selected from hydroxy, nitro, cyano,amino, tert-butyldimethylsilyloxy (TBSO), halogen, (C₁–C₆)alkyl,(C₁–C₆)alkoxy, (C₃–C₆)cycloalkyl, aryl, benzyloxy, acyl, carboxyl oracyloxy groups.
 4. The compound according to claim 1, wherein the cyclicstructure formed by Y² and Y³ is selected from substituted orunsubstituted benzene, pyridine, pyrrolidine, furan, thiophene,morpholine, piperazine or pyrrole.
 5. A compound of the formula (I) asdefined according to claim 1, which is selected from:(5R)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-oneor its salts;(5R)-3-[3-fluoro-4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-oneor its salts;3-{2-fluoro-4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;3-{2-fluoro-4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-6-methyl-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;3-{2-fluoro-4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-5-methyl-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;(5R)-5-hydroxymethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-2-oneor its salts;(5R)-3-[2-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-oneor its salts;(5R)-3-[3,5-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-hydroxymethyl-1,3-oxazolan-2-oneor its salts;(5R)-5-hydroxymethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;3-{4-[(5R)-5-hydroxymethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;(5R)-azidomethyl-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;3-{4-[(5R)-5-azidomethyl-2-oxo-1,3-oxazolan-3-yl]-2-fluorophenyl}-6-methyl-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;3-{4-[(5R)-5-azidomethyl-2-oxo-1,3-oxazolan-3-yl]-2-fluorophenyl}-5-methyl-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;(5R)-5-azidomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-2-oneor its salts;(5R)-5-azidomethyl-3-[2-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5R)-azidomethyl-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5R)-5-azidomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;3-{4-[(5R)-5-azidomethyl-2-oxo-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts;(5R)-aminomethyl-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5R)-5-aminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-2-oneor its salts;(5R)-5-aminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;N-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methanamideor its salts;N-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methanamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}propanamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}butanamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}pentanamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}heptanamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acrylamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-2,2,2-trifluoroacetamideor its salts;Ethyl(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethylcarbamoylmethanoate or its salts;N1-{(5S)-3-[3-fluoro-4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-3-[3-fluoro-4-(6-methyl-2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-3-[3-fluoro-4-(5-methyl-2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}propanamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}heptanamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}acrylamideor its salts;N1-{(5S)-3-[2-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}propanamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamideor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}acetamideor its salts;(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-oneor its salts;(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(3,3,3-trifluoro-1-thioxopropylaminomethyl)-1,3-oxazolan-2-oneor its salts; 3-{2-fluoro-4-[(5S)-2-oxo-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-3-yl]phenyl}-2,3-dihydrobenzo[d][1,3]oxazol-2-oneor its salts; (5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-oneor its salts;(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-oneor its salts;(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxopropylaminomethyl)-1,3-oxazolan-2-oneor its salts;(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-(1-thioxoethylaminomethyl)-1,3-oxazolan-2-oneor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylcarbamateor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}methylcarbamateor its salts;N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylcarbamateor its salts;N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylcarbamateor its salts;(5S)-5-methylthioxy(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methyldithiocarbamateor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamateor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamateor its salts;N1-{(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}trifluoroacetoxythiocarbamateor its salts; (5 S)-5-cyclohexyloxy(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;N1-{(5S)-3-[3-fluoro-4-(2-thioxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamateor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}methylthiocarbamateor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-1,3-oxazolan-3-yl)-3-trifluoromethylphenyl]-1,3-oxazolan-5-ylmethyl}ethylthiocarbamateor its salts;N1-{(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamateor its salts;N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}methylthiocarbamateor its salts;N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}ethylthiocarbamateor its salts;N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-1-propylthiocarbamateor its salts;(5S)-5-[2,2,2-trifluoroethyloxy(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts; (5S)-5-[2-hydroxyethyloxy(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts; (5S)-5-[2-methoxyethyloxy(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}allylthiocarbamateor its salts;N1-{(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-2-oxo-1,3-oxazolan-5-ylmethyl}-2-propylthiocarbamateor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-2,3-dihydrobenzol[d][1,3]oxazol-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}methylthiocarbamateor its salts;N1-{(5S)-2-oxo-3-[4-(2-oxo-2,3-dihydrobenzo[d][1,3]oxazol-3-yl)phenyl]-1,3-oxazolan-5-ylmethyl}ethylthiocarbamateor its salts;N1-((5S)-3-{4-[2-oxo-1,3-oxazolan-3yl]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-(N,N-dimethylamino)ethylthiocarbamateor its salts;(5S)-5-[(2S)-2-hydroxymethylazolan-1-yl(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts; (5S)-5-diethylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts; (5S)-5-allylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5S)-5-benzylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5S)-5-[4-methoxybenzylamino(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-[2-pyridylmethylamino(thioxo)methylaminomethyl]-1,3-oxazolan-2-one or its salts;(5S)-5-methylamino(thioxo)methylaminomethyl-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts; (5S)-5-[2-hydroxyethylamino(thioxo)methylaminomethyl]-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-[1,4-thiazinan-4-yl(thioxo)methylaminomethyl]-1,3-oxazolan-2-oneor its salts;(5S)-3-[4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-[2-pyridylamino(thioxo)methylaminomethyl]-1,3-oxazolan-2-oneor its salts;(5S)-5-amino(thioxo)methylaminomethyl-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5S)-3-[3-fluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-methylamino(thioxo)methylaminomethyl-1,3-oxazolan-2-one or its salts;(5S)-5-amino(thioxo)methylaminomethyl-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-1,3-oxazolan-2-oneor its salts;(5S)-3-[3,5-difluoro-4-(2-oxo-1,3-oxazolan-3-yl)phenyl]-5-methylamino(thioxo)methylaminomethyl-1,3-oxazolan-2-oneor its salts andN1-((5S)-3-{4-[2-oxo-1,3-oxazolan-3y]phenyl}-2-oxo-1,3-oxazolan-5-ylmethyl)-(N,N-dimethylamino)ethylthiocarbamatehydrochloride.
 6. A compound according to claim 1, wherein thepharmaceutically acceptable salt is selected from Li, Na, K, Ca, Mg, Fe,Cu, Zn, or Mn or salts of organic bases, chiral bases, natural aminoacids, unnatural amino acids, substituted amino acids, guanidine,substituted guanidine salts; ammonium, substituted ammonium salts,aluminum salts and acid addition salts.
 7. A pharmaceutical compositioncomprising a compound of formula (I)

as claimed in claim 1 and a pharmaceutically acceptable carrier,diluent, excipient or solvate.
 8. A pharmaceutical composition asclaimed in claim 7, in the form of a tablet, capsule, powder, syrup,solution or suspension.
 9. A method for treating a bacterial infectioncomprising administering an effective amount of a compound of formula(I) as claimed in claim 1 to a patient in need thereof.
 10. A method fortreating a bacterial infection comprising administering an effectiveamount of a pharmaceutical composition as claimed in claim 7 to apatient in need thereof.
 11. A pharmaceutical composition comprising acompound as claimed in claim 5 and a pharmaceutically acceptablecarrier, diluent, excipient or solvate.
 12. A pharmaceutical compositionas claimed in claim 11, in the form of a tablet, capsule, powder, syrup,solution or suspension.
 13. A method for treating a bacterial infectioncomprising administering an effective amount of a compound as claimed inclaim 5 to a patient in need thereof.
 14. A method for treating abacterial infection comprising administering an effective amount of apharmaceutical composition as claimed in claim 11 to a patient in needthereof.
 15. The compound according to claim 1, wherein the substituentson R^(a) are selected from hydroxy, halogen, nitro, amino, alkoxy,carboxy or cyano.
 16. A compound according to claim 6, wherein the saltsof organic bases are selected from N,N′-diacetylethylenediamine,betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol,N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine,hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine,piperidine, procaine, purines, theobromine, triethylamine,trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine,ethylenediamine, N,N′-diphenylethylenediamine,N,N′-dibenzylethylenediamine, N-benzyl phenylethylamine, choline,choline hydroxide, dicyclohexylamine, metformin, benzylamine,phenylethylamine, dialkylamine, trialkylamine, thiamine,aminopyrimidine, anilnopyridine, purine, or spermidine.
 17. A compoundaccording to claim 6, wherein the salts of chiral bases are selectedfrom alkylphenylamine, glycinol, phenyl glycinol.
 18. A compoundaccording to claim 6, wherein the salts of natural amino acids areselected from glycine, alanine, valine, leucine, isoleucine, norleucine,tyrosine, cystine, cysteine, methionine, proline, hydroxy proline,histidine, ornithine, lysine, arginine, serine, threonine, orphenylalanine.
 19. A compound according to claim 6, wherein the salts ofunnatural amino acid, substituted amino acids are selected fromD-isomers, guanidine, substituted guanidine wherein the substituents areselected from nitro, amino, alkyl selected from methyl, ethyl, andpropyl; alkenyl selected from ethenyl, propenyl, or butenyl; alkynylselected from ethynyl, or propynyl.
 20. A compound according to claim 6,wherein the addition salts are selected from sulphates, nitrates,phosphates, perchlorates, borates, halides, acetates, tartrates,maleates, citrates, succinates, palmoates, methanesulphonates,benzoates, salicylates, hydroxynaphthoates, benzenesulfonates,ascorbates, glycerophosphates, or ketoglutarates.
 21. A compoundaccording to claim 5, wherein the pharmaceutically acceptable salt isselected from Li, Na, K, Ca, Mg, Fe, Cu, Zn, or Mn or salts of organicbases, chiral bases, natural amino acids, unnatural amino acids,substituted amino acids, guanidine, substituted guanidine salts;ammonium, substituted ammonium salts, aluminum salts and acid additionsalts.
 22. A method for treating a bacterial infection comprisingadministering an effective amount of a pharmaceutical composition asclaimed in claim 8 to a patient in need thereof.
 23. A method fortreating a bacterial infection comprising administering a pharmaceuticalcomposition as claimed in claim 12 to a patient in need thereof.